Entities

Jasmine Li is publicly named by Swinburne in its university innovation/commercialisation support directory as Manager, Intellectual Property Commercialisation. This is an affiliated university support role, not a verified direct employment or director appointment at the legal investment company.

Audrey Jean-baptiste is publicly named by Swinburne in its university innovation/commercialisation support directory as Associate Director, Programs and Operations. This is an affiliated university support role, not a verified direct employment or director appointment at the legal investment company. The live directory marks this person on maternity leave.

Zahra Shahbazian is publicly named by Swinburne in its university innovation/commercialisation support directory as Founder in Resident, Commercial Innovation. This is an affiliated university support role, not a verified direct employment or director appointment at the legal investment company.

Cynthia Bernard is publicly named by Swinburne in its university innovation/commercialisation support directory as Administration Support Officer. This is an affiliated university support role, not a verified direct employment or director appointment at the legal investment company.

Masha Pelipas is publicly named by Swinburne in its university innovation/commercialisation support directory as Program Manager, Accelerator & Flagship Initiatives. This is an affiliated university support role, not a verified direct employment or director appointment at the legal investment company.

Jamshaid Akbar is publicly named by Swinburne in its university innovation/commercialisation support directory as Investment Manager, Student Ventures. This is an affiliated university support role, not a verified direct employment or director appointment at the legal investment company.

Liya Ma is publicly named by Swinburne in its university innovation/commercialisation support directory as Commercialisation Manager – Innovative Planet. This is an affiliated university support role, not a verified direct employment or director appointment at the legal investment company.

Olivia Rinato is publicly named by Swinburne in its university innovation/commercialisation support directory as Associate Director, Programs and Operations. This is an affiliated university support role, not a verified direct employment or director appointment at the legal investment company.

Tathagath Mariswamy is publicly named by Swinburne in its university innovation/commercialisation support directory as Commercialisation Manager – Space and Aerospace. This is an affiliated university support role, not a verified direct employment or director appointment at the legal investment company.

Heath Evans is publicly named by Swinburne in its university innovation/commercialisation support directory as Associate Director, Climate Tech Hub. This is an affiliated university support role, not a verified direct employment or director appointment at the legal investment company.

Rob Scott is publicly named by Swinburne in its university innovation/commercialisation support directory as Associate Director, Commercialisation Health & MedTech. This is an affiliated university support role, not a verified direct employment or director appointment at the legal investment company.

Shane Kilcullen is publicly named by Swinburne in its university innovation/commercialisation support directory as Associate Director, Commercialisation Innovative Planet. This is an affiliated university support role, not a verified direct employment or director appointment at the legal investment company.

Tom Forbes is publicly named by Swinburne in its university innovation/commercialisation support directory as Associate Director Commercialisation - Student & Early Stage Ventures. This is an affiliated university support role, not a verified direct employment or director appointment at the legal investment company.

Abhay Seth is publicly named by Swinburne in its university innovation/commercialisation support directory as Director, Commercial Innovation. This is an affiliated university support role, not a verified direct employment or director appointment at the legal investment company.

Chair of the ACC Innovation Program, supporting clinical adoption of emerging cardiovascular technologies.

President and CEO of MedAxiom, the ACC subsidiary, listed within College executive leadership. A cardiologist with health-system management and advanced-imaging experience.

Swinburne Ventures Ltd (also styled Swinburne Ventures Limited), ABN47096584404 and ACN096584404, is Swinburne University of Technology’s controlled commercial-investment arm in Australia. University reporting identifies a company limited by guarantee and 100% university control; it is distinct from the parent university and does not imply a stock-exchange listing. It supports technology-based pre-seed and seed ventures, research spin-outs and equity-based commercialisation partnerships. Its disclosed portfolio includes CogTx neuroscience software, Novapep neurodegenerative therapeutics, EntroMat advanced materials, Fluency documentation software, Vidversity digital learning and Vycarb carbon-removal technology. Werner van der Merwe is publicly identified as chair. The associated Innovation Studio and Commercial Innovation team provide commercialisation support; their university titles are explicitly qualified rather than presented as all being employees or directors of the legal investment company. The image is the authentic shared university brand used on its investment/commercialisation pages; no separate unit logo is published. No external final fund close amount or date is verified.

Chief people officer of ACC, overseeing employee development, engagement and operations, with prior accounting and human-resources experience.

Chief medical officer and past president of ACC, with cardiovascular quality, drug safety and sports-cardiology interests.

ACC health-equity and inclusion leader, a cardiologist with clinical research experience in heart failure and healthcare disparities.

ACC executive vice president, COO and CFO, responsible for finance, technology and digital transformation. Joined inJuly2021 after consultancy leadership at Publicis Sapient.

Senior executive vice president of ACC, overseeing strategy, communications, business development, international affairs and science/quality. Previously worked in healthcare research and consulting.

General counsel of ACC, specializing in nonprofit and healthcare legal affairs. Previously an attorney at Venable.

Chief executive officer of ACC, with prior College finance, people and operations leadership and accounting experience.

ACC trustee with organizational and business leadership experience.

ACC trustee and cardiovascular clinician.

ACC trustee with healthcare quality expertise.

ACC trustee focused on cardiovascular prevention.

ACC trustee and cardiologist.

Adam Seskis is a non-executive director of Cognitive Therapeutics Pty Ltd (CogTx), according to Dementia Australia Research Foundation’s current biography. He is chief executive of RMS and has more than 25 years of technology, software, payments and commercial leadership experience.

ACC trustee with cardio-oncology research expertise.

ACC trustee and cardiac electrophysiologist.

ACC trustee and cardiovascular clinician.

ACC governors chair-elect and cardiologist.

Graeme Samuel AC chairs Cognitive Therapeutics Pty Ltd (CogTx). He is a Monash Business School professor and former chair of the Australian Competition and Consumer Commission, with dementia-research and public-policy governance experience.

ACC trustee and heart-failure cardiologist.

ACC secretary and governors chair, with cardiovascular imaging expertise.

ACC treasurer and practicing cardiologist.

CogTx, legally Cognitive Therapeutics Pty Ltd (ABN 72 681 458 408; ACN 681 458 408), is a Melbourne medical technology spinout developing software to personalize transcranial magnetic stimulation (TMS). Its technology uses MRI scans and advanced algorithms to identify individual brain-stimulation targets, aiming to simplify clinical planning and reduce reliance on costly mapping equipment. The software was co-invented by Bionics Institute researchers Kate Hoy, Oscar Murphy and David Hill. CogTx emerged from the strategic partnership between the Bionics Institute and Swinburne University of Technology, with Planet Innovation providing software-development expertise. Swinburne’s September 9, 2026 launch announcement confirms secured seed funding from Swinburne Ventures Ltd, Australian family offices and medtech entrepreneurs; neither the total amount nor the unnamed private investors’ identities are disclosed. Graeme Samuel chairs the company and Adam Seskis is a publicly named non-executive director. Kate Hoy is identified as chief scientific officer in ACMD’s current speaker biography. Development toward expected FDA approval and worldwide clinical deployment remains a future objective. Personalized TMS research for Alzheimer’s disease is investigational; general clinical use of TMS for other conditions does not establish approval of this software or efficacy in Alzheimer’s. The company is distinct from the US listed drug developer Cognition Therapeutics and from Cognito Therapeutics’ CogTx-001 sensory-stimulation device.

Immediate-past ACC president and cardiovascular imaging specialist.

ACC vice president and cardiac surgeon.

The American College of Cardiology (ACC) is a nonprofit cardiovascular professional society founded in1949, headquartered at Heart House in Washington, DC. It supports clinicians through education, research publishing, clinical guidelines, registries, accreditation and health-policy advocacy. Its January2026 bylaws identify the College as a District of Columbia nonprofit corporation exempt under Section501(c)(6). The related American College of Cardiology Foundation is a separate501(c)(3) corporation with ACC as its sole member; charitable gifts and educational grants support the Foundation. This institutional profile represents the named College rather than an independent venture manager. ACC’s relevance to AI is grounded in its Innovation Program, clinical AI resources and actual participation in Cleerly’s2021 SeriesB financing for AI-based coronary imaging. Its current published national leadership includes fifteen officers/trustees, eight executive staff leaders and Innovation Program chair Fred Masoudi. The executive directory identifies MedAxiom’s president and CEO as a subsidiary leader, rather than College CEO. Former innovation chief Ami Bhatt is explicitly reported to have departed for WHOOP in the September2026 magazine. Institution revenues, donations, endowment support and subsidiary governance are distinct from closed venture funds; no independent VC fund close or institutional fundraising round is verified here.

ACC president and interventional cardiologist studying cardiovascular outcomes.

Rahul Talwar is named by neuro42, Inc. in its2024 SEC FormD as Board Director (SEC September2024 filing; current status unverified). The filing establishes this legal affiliation at that time; it does not independently establish a current operating title, professional background or personal investment.

Shibu Gangadharan is named by neuro42, Inc. in its2024 SEC FormD as Executive Officer (SEC June2024 filing; current status unverified). The filing establishes this legal affiliation at that time; it does not independently establish a current operating title, professional background or personal investment.

Steve Favaloro is published by Kineticos Life Sciences as Strategic Advisor. Steve Favaloro is currently the Chief Financial Officer of Arranta Bio, a best in class microbiome CDMO. Steve also currently advises several early stage biotech companies, helping them to architect their financial and fundraising strategy. He was formerly the Chief Financial Officer at Brammer Bio, with responsibility for overseeing the financial health and information systems during a period of rapid growth and the execution of a $200M capacity expansion program. Steve received his BA in Economics from Boston College, and an MS in Finance and an MBA from the Carroll School of Management at Boston College. Outside-company appointments in this source summarize published experience; no additional current external employer, directorship or personal investment check is inferred.

Nathan Finger is published by Kineticos Life Sciences as Strategic Advisor. Nathan is the Director of Operations at Kinvard Bio, a Kineticos AMR Accelerator Fund I portfolio company, contributing his operational and strategic expertise to further expand innovation in the life sciences sector. Nathan previously served as Director at Kineticos, focused on sourcing opportunities, conducting diligence, leading deal execution, and working with portfolio companies. Mr. Finger had been with Kineticos since 2015 in a variety of roles in business development, marketing, and operations, gaining deep expertise across a variety of markets within the life sciences. Mr. Finger has used his experience to support Kineticos' Disruptor Fund Series and Kineticos AMR Accelerator Fund in building their portfolios. Nathan brings years of experience in life science investing and venture capital, marketing, business development, primary research, strategy, and commercial operations to Kineticos. He earned his B.S. in Business Administration with a concentration in Marketing from NC State University. Outside-company appointments in this source summarize published experience; no additional current external employer, directorship or personal investment check is inferred.

Mike Nicholson is published by Kineticos Life Sciences as Principal; Strategic Advisor (directory category). Mike Nicholson, PhD is a Principal at Kineticos Ventures, leading the technical diligence process for potential investments. Additionally, Dr. Nicholson shares his expertise with portfolio and non-portfolio companies through positions on Scientific Advisory Boards. Before joining Kineticos, Dr Nicholson was President and Chief Operating Officer at Inceptor Bio, Kineticos’ first foundry company. Prior experience includes leadership roles at BioAgilytix and Precision BioSciences. Dr. Nicholson earned his BS in chemistry from SUNY Brockport, his PhD in molecular biology and genetics from the Johns Hopkins School of Medicine, and carried out postdoctoral research at the University of North Carolina, Chapel Hill. Outside-company appointments in this source summarize published experience; no additional current external employer, directorship or personal investment check is inferred.

Mark Gilbert is published by Kineticos Life Sciences as Strategic Advisor. Mark Gilbert, M.D. is the founding Chief Medical Officer at Juno Therapeutics. Prior to joining Juno, Dr. Gilbert served as an interim Chief Medical Officer and consultant in strategic drug development and portfolio management in medical oncology for several U.S. biotechnology and pharmaceutical companies. Prior to these positions, Dr. Gilbert was a faculty member at the Fred Hutchinson Cancer Research Center and the University of Washington in Seattle and trained in the laboratory of Dr. Phil Greenberg, one of Juno’s scientific co-founders. Dr. Gilbert earned a BS degree in biochemistry from the University of Iowa and an MD from the University of Iowa Medical School in Iowa City, Iowa. Outside-company appointments in this source summarize published experience; no additional current external employer, directorship or personal investment check is inferred.

Dave Ousterout is published by Kineticos Life Sciences as Strategic Advisor. Dave Ousterout, Ph.D., is Co-Founder and Chief Scientific Officer for Locus Biosciences. Dr. Ousterout’s expertise is in protein engineering and early-stage applications of new technologies to treat human diseases. He completed his doctoral studies at Duke University in the lab of Dr. Charles Gersbach, where he developed novel gene-editing approaches for correcting mutations that cause Duchenne muscular dystrophy. Dr. Ousterout earned a B.S. in Biological & Environmental Engineering from Cornell University, an MS in Biomedical Engineering from Duke University and a Ph.D. in Biomedical Engineering from Duke University. Outside-company appointments in this source summarize published experience; no additional current external employer, directorship or personal investment check is inferred.

David King is published by Kineticos Life Sciences as Strategic Advisor. Mr. King was most recently the Chief Executive Officer of LabCorp (NYSE: LH) from 2007 to 2019. At LabCorp, Mr. King also served as the Executive Chairman of the Board from November 2019 to May 2020, and as the Non-Executive Chairman of the Board from May 2009 to October 2019. Mr. King is the board chair of PATH and was appointed in 2017 to the advisory board for Duke University’s Robert J. Margolis, MD, Center for Health Policy. Mr. King previously served on the board of Cardinal Health (NYSE: CAH), Elon University and the American Clinical Laboratory Association, where he served as board chair from 2010 to 2014. Mr. King is also on the board of The Emily K Center, a college-readiness center in Durham, North Carolina, founded by Mike Krzyzewski, the head coach of the Duke University Men’s Basketball team. Mr. King received a bachelor’s degree, cum laude, from Princeton University and a Juris Doctor, cum laude, from the University of Pennsylvania Law School. Outside-company appointments in this source summarize published experience; no additional current external employer, directorship or personal investment check is inferred.

Dan McCormick is published by Kineticos Life Sciences as Strategic Advisor. Dan McCormick brings over 25 years of experience in biopharma, devices, and diagnostics. He has built highly collaborative cross-organizational teams to drive incremental revenues in multiple U.S. and ex-U.S. markets. Dan leverages analytics, efficient channels, and technologies to develop strategic solutions that focus investments for highest impact. His broad perspective is a culmination of experience that spans numerous sales, marketing, and strategy roles. Mr. McCormick is a Vice President for a leading consulting firm focused on commercialization and market access. He serves as a board member for Promaxo, a medical technology company that develops and commercializes MRI systems. He also serves as an advisory board member for Kickstart Venture Services, a UNC Chapel Hill organization that helps facilitate and accelerate start-up companies spinning out of the University. Mr. McCormick holds an M.B.A from Campbell University, and a B.S. in business administration from the UNC Chapel Hill. A frequently solicited industry conference speaker, Dan’s topics have included “Creating Sustainable Change,” “Channel Optimization in Pharma,” “Selling Value Through Technology,” and “Strategies for a Customer-Centric Approach to Business Growth.” Accolades include: PHARMAfield UK Magazine’s “Movers & Shakers” and PM360 Magazine’s “2018 Innovators” award. Outside-company appointments in this source summarize published experience; no additional current external employer, directorship or personal investment check is inferred.

Chris Heery is published by Kineticos Life Sciences as Strategic Advisor. Dr Christopher Heery is the Chief Medical Officer of Arcellx. There, he oversees the development of their lead asset, CART-ddBCMA, as well as the ARC-sparX platform of modular CAR T cells which may improve CAR T cell capabilities via multiple antigen targeting and controlled cell expansion. Previously, he has served as Chief Medical Officer of Precision BioSciences and Bavarian Nordic. At Precision, he oversaw the clinical development of one of the first allogeneic CAR T cell platforms and provided clinical insight into clinical efforts for gene editing therapeutics. While at Bavarian Nordic, he oversaw clinical development programs for its immune-oncology and infectious disease vaccine portfolio. Prior to his roles in biotech, he was head of the Clinical Trials Group of the Laboratory of Tumor Immunology and Biology at the National Cancer Institute (NCI). He joined the NCI Medical Oncology Branch as a Medical Oncology Fellow in 2009 and held an Adjunct Appointment in the Genitourinary Malignancies Branch. At NCI, Dr Heery was part of the larger effort of the Laboratory of Tumor Immunology and Biology to create new immunotherapies for the treatment of cancer. Dr Heery is board certified in Medical Oncology and Internal Medicine and completed his internal medicine residency at the University of Illinois at Chicago after receiving his MD from East Carolina University Brody School of Medicine. Dr Heery also holds a BA in English Literature from Duke University. Outside-company appointments in this source summarize published experience; no additional current external employer, directorship or personal investment check is inferred.

Bruce Thompson is published by Kineticos Life Sciences as Strategic Advisor. Bruce is the CEO of Kincell Bio, bringing over 28 years of experience to his position. Prior to his role with Kincell Bio, LLC., Bruce was Vice President and Technical Lead for the Cell Therapy Franchise at Resilience, Inc., where he helped to build the development and GMP manufacturing capabilities and served as a technical advisor both internally and externally. He has over 18 years of CMC strategy, product development and cell therapy manufacturing experience. In his first startup role, he was Vice President of Process Sciences at Lyell Immunopharma, where he was responsible for Process and Analytical Development, as well as tech transfer of processes and methods to a newly built state-of-the-art cGMP facility. Prior to Lyell, Bruce served as the Sr. Director of the Therapeutic Products Program at Fred Hutchinson Cancer Research Center (FHCRC), where he led GMP manufacturing of cell and gene therapy products. He was responsible for supporting >15 active clinical programs and contributed to the filing of 6 INDs for various cell therapy programs. As part of his early career development, Bruce spent nearly 10 years at Pfizer in the Pharmaceutical Sciences division where he gained expertise in analytical and process development. Bruce received his B.A. in Biology, an M.S. in Biochemistry from The Ohio State University and Ph.D. in Microbiology and Immunology from the University of Louisville. Outside-company appointments in this source summarize published experience; no additional current external employer, directorship or personal investment check is inferred.

Nigel Walker is published by Kineticos Life Sciences as Venture and Operating Partner. Nigel Walker is the Founder and Life Sciences Investor at the marketing firm “That’s Nice,” a full-service agency providing a breadth of capabilities including research, business strategy, messaging development, and consulting. With 35 years of experience in entrepreneurial business management, sales, and brand marketing, and 25 years in the pharma market, Nigel harnesses the capabilities of That’s Nice to help companies research future trends, communicate their marketing vision, and achieve business growth goals. He earned a BA with honors from London College. Outside-company appointments in this source summarize published experience; no additional current external employer, directorship or personal investment check is inferred.

Marc Wolff is published by Kineticos Life Sciences as Venture and Operating Partner. Marc Wolff brings more than 23 years of experience in the life sciences industry in various global general management and finance leadership roles. Prior to joining Calviri, Marc Wolff served as Chief Operating Officer and Chief Financial Officer of Aldevron, where he played a key role in scaling the company through exponential growth, enabling Aldevron’s clients to access essential GMP materials for their novel applications in gene and cell therapy. During his tenure, employees grew from 150 to 560 in little over two years, and the company built the world’s largest GMP plasmid DNA and GMP mRNA facility. Prior to Aldevron, Mr. Wolff was instrumental in supporting the growth of a clinical stage specialty pharmaceutical company and oversaw the successful completion of two private equity backed life science company mergers. Additionally, he spent fifteen years with Cardinal Health and Catalent in global general management and finance executive roles. Outside-company appointments in this source summarize published experience; no additional current external employer, directorship or personal investment check is inferred.

Michael Chambers is published by Kineticos Life Sciences as Venture and Operating Partner. Mr. Chambers co-founded Aldevron in 1998, holding the positions of President and Chief Executive Officer until 2020. Mr. Chambers is now Executive Chairman of the Board of Directors of Aldevron. Using a technology platform that Mr. Chambers co-invented, Aldevron started producing plasmid DNA for biotech researchers in a small lab on the campus of North Dakota State University (NDSU). Aldevron specializes in the contract production of nucleic acids (e.g., plasmids, mRNA), recombinant proteins, and antibodies generated via genetic immunization and provides novel proteins like Cas9 variants and enhanced enzymes for in vitro mRNA transcript production. In recognition of his significant contributions, Mr. Chambers was named as one of the “100 Most Intriguing Entrepreneurs” by Goldman Sachs in 2018. Mr. Chambers also serves on the Board of Directors of Calviri, a fully integrated healthcare company. He received Bachelor of Science degrees in biotechnology, chemistry, and microbiology from NDSU. Outside-company appointments in this source summarize published experience; no additional current external employer, directorship or personal investment check is inferred.

John Ballantyne is published by Kineticos Life Sciences as Venture and Operating Partner. Dr. Ballantyne has over 23 years of experience in the development and manufacture of DNA, RNA and proteins across the research, diagnostic and licensed drug product spectrum. He co-founded Aldevron (now a Danaher operating company) directly out of graduate school in 1998 and has served as its Chief Scientific Officer since inception. Much of his focus outside of industrialization of biologicals manufacturing has been dedicated to working with military researchers to produce countermeasures to high threat/weaponizable viruses and in the development of systems for “n of 1” therapies in the oncology space. Dr. Ballantyne also has an interest in the anti-cancer and molecular-adjuvanting properties of a novel class of superantigens and has supported the technical and clinical maturation of these moieties through his research and development group for over a decade. His areas of expertise include large-scale biologicals production, purification systems and novel ligand/matrix designs, pharmacokinetics, and clinical path forward design and support. Dr. Ballantyne received his undergraduate degrees in Pharmacy at the Central Institute of Technology and the University of Otago in New Zealand and his doctorate from the Department of Pharmaceutical Sciences at North Dakota State University. Outside-company appointments in this source summarize published experience; no additional current external employer, directorship or personal investment check is inferred.

George Fotiades is published by Kineticos Life Sciences as Venture and Operating Partner. George Fotiades is a recognized chief executive who has led global, complex companies through significant change — the kind that accompanies development and marketing of major new products and services, creating organizational capabilities on a global scale, securing a broad range of strategic acquisitions, and integrating businesses to create unified operating companies. Beginning in early 2019, Fotiades served as CEO of Cantel Medical, a leader in infection prevention solutions serving the medical and dental markets. During his tenure, Fotiades implemented several organic growth initiatives to expand global leadership of the endoscopy reprocessing market, successfully navigated the impact of the Covid pandemic to emerge with a stronger market presence, completed a $775 mil transformational acquisition to become the clear market leader in dental office infection prevention, and led a significant strategic sale to Steris Corporation in June 2021 for $4.6B, a ~17x EBITDA multiple. George Fotiades serves as chairman of the board of AptarGroup (NYSE: ATR), the leading global supplier of dispensing systems for a broad range of consumer and healthcare products, and as a director of ProLogis (NYSE: PLD), the leading global provider of distribution facilities and services. Fotiades holds a bachelor’s degree in economics from Amherst College and a master’s degree from Kellogg School of Management at Northwestern. Outside-company appointments in this source summarize published experience; no additional current external employer, directorship or personal investment check is inferred.

Douglas Thomson is published by Kineticos Life Sciences as Venture and Operating Partner. Douglas Thomson is Chief Executive Officer and co-founder at Pneumagen a clinical stage infectious disease business. Prior to co-founding Pneumagen, he led executive teams generating rapid value creation at companies such as GT Biologics a part of 4D Pharma. His background is in infectious disease vaccine research and development. He was previously at SingVax, in Singapore, as CEO, and Microscience Ltd as Business Development Director. Douglas currently sits on the board of Omideon, a St. Andrews based biotech company focused on the development of novel treatments for cancer. He is also a non-executive director at EnteroBiotix, a microbiome therapeutics platform and product company. Outside-company appointments in this source summarize published experience; no additional current external employer, directorship or personal investment check is inferred.

Derek Hennecke is published by Kineticos Life Sciences as Venture and Operating Partner. Derek was the Founder and CEO of Xcelience, a Florida-based contract development and manufacturing company that specialized in developing clinical Phase I-III drug product. He started the company in 2006 and sold it to a large multinational in 2016. He is currently a Board Member for The Friedreich’s Ataxia Research Alliance. Derek received his BSC from the University of Alberta and his MBA from RSM Erasmus University. Outside-company appointments in this source summarize published experience; no additional current external employer, directorship or personal investment check is inferred.

Afshin Safavi is published by Kineticos Life Sciences as Venture and Operating Partner. Afshin Safavi, Ph.D., is a veteran biochemist who has extensive experience in establishing and leading bioanalytical teams in support of the development of biological products in preclinical and clinical-trial laboratories in pharmaceutical, biotechnology, manufacturing companies and Contract Research Organizations (CROs). Prior to founding BioAgilytix Labs, he was the Director of Ligand Binding and Immunoassay, operating under Good Laboratory Practices (GLP) at AAIPharma. At Talecris BioTherapeutics, he led the Preclinical and Clinical Assay Development team, building on his experience as a senior scientist at Nobex Corporation, GlaxoSmithKline and IGEN International. He is considered an expert in the area of immunoassay with a wide working knowledge of various platforms. Dr. Safavi gives lectures at local universities, has numerous peer reviewed journal publications, poster and podium presentations at national and internal conferences and a book chapter. He obtained his B.S. in Biochemistry from UCLA, his Ph.D. in Biochemistry from University of Kentucky Medical School, Department of Biochemistry and completed a two-year postdoctoral assignment at the Emory University, Department of Pathology. Outside-company appointments in this source summarize published experience; no additional current external employer, directorship or personal investment check is inferred.

Abe Maingi is published by Kineticos Life Sciences as Venture and Operating Partner. Abe Maingi is Chief Business Officer at Inceptor Bio. Prior to his current role, he spent seven years at Kineticos Life Sciences, an award-winning life sciences advisory firm, serving in roles of increasing responsibility. He is an Operating Partner in the Kineticos Disruptor Fund and serves as a board observer for Promaxo, a medical technology company that develops and commercializes customer-centric MRI systems and MRI-based technologies. He serves as Adjunct Faculty at University of North Carolina at Chapel Hill. Abe received his BA in Business Administration from Campbell University. Outside-company appointments in this source summarize published experience; no additional current external employer, directorship or personal investment check is inferred.

Shailesh Maingi is published by Kineticos Life Sciences as Founder, Managing Partner. Shailesh Maingi is the Founder and Managing Partner of Kineticos Life Sciences. He serves on the Investment Committees of all Kineticos funds and plays an active role in guiding portfolio companies, supporting growth, and helping management teams achieve operational objectives. Prior to founding Kineticos Life Sciences LLC, Mr. Maingi was a senior executive at Cardinal Health and Sigma-Aldrich. He started his career as a research and development scientist with Roche Diagnostics. Shailesh is also the Founder and Chair of Inceptor Bio, LLC, a clinical stage biotechnology company advancing next-generation CAR-T therapy. In addition, Shailesh currently serves on the board of Kincell Bio, eXmoor Pharma, Orthobond and Kinvard Bio. He previously served on the boards of Gallus Biopharmaceuticals, Arranta Bio and Locus Biosciences. He is adjunct faculty at UNC Kenan-Flagler School of Business and founded the InVincible Cancer Research Fund Outside-company appointments in this source summarize published experience; no additional current external employer, directorship or personal investment check is inferred.

Richard Snyder is published by Kineticos Life Sciences as KAMRA I Investment Committee Member. Richard Snyder, Ph.D. is the Vice President of Science and Technology, Pharma Services at Thermo Fisher Scientific. Prior to joining Thermo Fisher Scientific, Dr. Snyder was a co-founder and Chief Scientific Officer at Brammer Bio. In addition to scientific leadership roles in industry, he was an Associate Professor of Molecular Genetics and Microbiology, and Director of Biotherapeutic Programs at the University of Florida; an Assistant Professor of Pediatrics at Harvard Medical School; and a postdoctoral fellow at Johns Hopkins University School of Medicine. Dr. Snyder received his doctoral degree in Microbiology from The State University of New York at Stony Brook and obtained his BA in Biology from Washington University in St. Louis. Outside-company appointments in this source summarize published experience; no additional current external employer, directorship or personal investment check is inferred.

Keith Capecci is published by Kineticos Life Sciences as Principal. Keith Capecci is a Principal at Kineticos Life Sciences. He is responsible for deal sourcing, structuring and negotiation, monitoring current investments, and supports day-to-day firm operations (including finance and investor relations). In addition, he currently serves as a board observer of Kincell Bio and Inceptor Bio. Keith has been in Private Markets for more than a decade. Most recently he was a Vice President at Gabriel Horn Capital, a boutique fund placement advisory firm. Prior to Gabriel Horn Capital, he was a Vice President at IFC Investment Management, an agribusiness investment manager. Keith started his career in private markets at Hamilton Lane, a leading, global investment manager providing private markets solutions. Keith earned his MBA from Saint Joseph’s University and BA from Villanova University. Outside-company appointments in this source summarize published experience; no additional current external employer, directorship or personal investment check is inferred.

Mark Bamforth is published by Kineticos Life Sciences as KAMRA I Investment Committee Member. Mark Bamforth is a General Partner in the Kineticos Anti-Microbial Resistance Accelerator (KAMRA) Fund I. Previously, Mr. Bamforth founded, grew and sold three PE-backed contract development and manufacturing organizations (CDMO); specifically, Arranta Bio, founded in 2019 to focus on the microbiome, which was sold to Recipharm in 2022, Brammer Bio, which was founded in 2015, supporting cell and gene therapies, and was acquired by Thermo Fisher Scientific in 2019, and Gallus Biopharmaceuticals, founded in 2010 to manufacture mAbs, and was sold to Patheon in 2014. Prior to this, Mr. Bamforth was the head of global operations at Genzyme Corporation. Mr. Bamforth serves on the boards of Enterobiotix, Pneumagen, Continuus Pharmaceuticals, Kincell Bio, and Entrepreneurial Scotland. Mr. Bamforth has a BS in Chemical Engineering from Strathclyde University and an MBA from Henley Management College. Outside-company appointments in this source summarize published experience; no additional current external employer, directorship or personal investment check is inferred.

Geordan Davis is published by Kineticos Life Sciences as Analyst. Geordan Davis first joined Kineticos as a summer intern during his penultimate year at university through Entrepreneurial Scotland’s Saltire Scholars Programme. After graduating with a First Class degree in Mathematics, Statistics and Finance from the University of Strathclyde, he returned to Kineticos as an analyst focused on investment analysis, financial modelling, commercial due diligence, and market research. With a background in quantitative finance, statistics, and corporate finance, Geordan brings a data driven approach to evaluating companies, markets, and growth opportunities. In his role, he supports the assessment of innovative life science businesses and contributes to investment work aimed at advancing companies with the potential to improve patient outcomes. Outside-company appointments in this source summarize published experience; no additional current external employer, directorship or personal investment check is inferred.

Frank Lis is published by Kineticos Life Sciences as General Partner. Mr. Lis serves as the President, the Chief Executive Officer, and a member of the Board of Managers of Kineticos Ventures and, along with Mr. Maingi, controls the General Partner. In addition to serving on the Investment Committee, Mr. Lis expects to be active in sourcing new investment opportunities and overseeing active portfolio companies for the Fund. Mr. Lis has over 30 years of experience as a senior executive in the pharmaceutical and biotechnology areas and has an extensive background in drug development, manufacturing, supply chain, quality systems, and commercial operations. Prior to joining Kineticos Ventures, Mr. Lis served as a senior executive at leading pharmaceutical services firms. Mr. Lis also serves as a board member and advisor to a number of start-up biotechnology companies. Most recently, Mr. Lis was President of Sharp Clinical Services with responsibility for the global drug development business unit of UDG Healthcare plc. Prior to that, Mr. Lis was Vice President and General Manager at Catalent Pharma Solutions, responsible for managing the clinical supply services business with sites in the United States, the United Kingdom, and Germany. In addition to his operational responsibilities, Mr. Lis has led the diligence, investment, and integration of numerous acquisitions during his career. Mr. Lis earned a Bachelor of Science in General Science from Villanova University. Outside-company appointments in this source summarize published experience; no additional current external employer, directorship or personal investment check is inferred.

Dilán Rivera is published by Kineticos Life Sciences as Senior Analyst. Dilán Rivera first started working at Kineticos as a business development intern. After a year, he joined as an analyst focused on scientific due diligence, commercial strategy, and primary research. In his role, he supported both the operations side of the company as well as business development and thought leadership activities. Dilan recently joined Kineticos Ventures as a senior analyst where he helps evaluate cell and gene therapy and AMR-focused opportunities. He earned his Master’s in Microbial Biotechnology from NC State University where he worked with several biotech companies in the RTP area on consulting projects. Now he hopes to use the skills he gained in graduate school to help improve patients’ lives by supporting the development of cell and gene therapy and AMR businesses. Outside-company appointments in this source summarize published experience; no additional current external employer, directorship or personal investment check is inferred.

Andrew Hoke is published by Kineticos Life Sciences as Analyst. Andrew Hoke is an analyst with experience in M&A, financial modeling, valuation, strategic analysis, and due diligence. He has supported live and prospective transactions across a variety of industries by developing financial models, conducting company and industry diligence, valuation analyses, and preparing materials for transaction advisory engagements. Prior to joining Kineticos, Andrew worked with a Midwest regional independent investment bank & registered broker-dealer, where he contributed to M&A transactions, capital raises, and strategic advisory projects. Earlier roles in pharmaceutical manufacturing strengthened his analytical & operational capabilities through commercial operations, financial planning, and pharmaceutical supply chain analysis. Andrew enjoys evaluating complex business opportunities by combining financial analysis with strategic thinking and has experience in healthcare, life sciences, and other early-stage companies. Andrew earned a Bachelor’s in Economics with a minor in Business from Miami University. Outside-company appointments in this source summarize published experience; no additional current external employer, directorship or personal investment check is inferred.

Sid Trivedi is a Partner at Foundation Capital; his current employer confirms he previously invested at Omidyar Technology Ventures. The OTV2017 official directory listed him as Associate following roles at Symphony Technology Group and Barclays. His historical OTV work included enterprise software and cybersecurity companies. His existing Foundation Capital role is retained.

Asepha builds AI infrastructure and workflow software for pharmacies. Its agents automate prescription intake and data entry, patient calls, benefits investigation, prior authorization and administrative coordination, while routing clinical questions to pharmacists. Its platform brings pharmacy operations into configurable workflows, including scheduling, reporting, shipment management and patient or provider portals. The company’s CareLink and Care Coordinator tools connect pharmacies with providers, payers and patients to reduce delays in specialty medication access.

Atlas Discovery is an AI-native pharmaceutical company developing autonomous research agents to identify new uses for existing drugs and reduce the work needed to design and run clinical trials. It combines biomedical data, models of patient drug response and agent systems that search evidence, generate hypotheses and predict clinical trial outcomes. Its research includes foundation models trained on preclinical and clinical data. A drug-repurposing candidate for cerebral cavernous malformation is undergoing preclinical testing with Alliance to Cure Cavernous Malformation; this is a research programme, not an approved treatment for that disease.

Basetwo AI builds a physics-informed AI platform that helps pharmaceutical, specialty-chemical and personal-care manufacturers optimize production. Engineers combine process data with physical models to build digital twins, simulate operating changes and receive recommendations on production parameters, yield, quality and cycle time. Its low-code tools support process development and scale-up, predictive quality measurements and production optimization; the company is also developing real-time autonomous process control through its AutoPilot technology.

LatentSpin develops an early-access platform that lets knowledge workers create and teach AI agents for recurring enterprise workflows. Users define inspectable workflow blocks and improve agents through examples, corrections, approvals and execution outcomes. The platform combines workflow orchestration, human review, audit trails and bounded in-model learning, with the aim of turning a team’s expertise into durable behavior in its own agents. Target workflows include healthcare operations, financial-services analysis, compliance, IT and logistics.

Co-founder and CTO of Asepha; previously worked at AMD on the MI300X chip. Leads the platform’s engineering and AI development.

Co-founder listed by Y Combinator; previously a member of technical staff at Origin Bio, with theoretical biology work at Johns Hopkins School of Medicine and mathematics at Dartmouth. No specific current C-suite title published in the reviewed primary directory.

Partner at Core Innovation Capital, as currently published by Asepha. Listed in its joint board/advisor section; exact seat type not individually specified. A July2025 financing release quotes Edwin Loredo at Core Innovation Capital; no name-change or equivalence inferred without additional primary proof.

Licensed pharmacist and Asepha co-founder. Doctor of Pharmacy from the University of British Columbia, with inpatient experience at BC Children’s Hospital and outpatient experience at Shoppers Drug Mart.

Partner at .406 Ventures; listed as a LatentSpin board director on his public investing profile.

Previously worked at Johnson & Johnson and Eversana.

Named alongside Shaamil Karim and Christian Gensbigler in the founder-authored Y Combinator launch as a co-founder of Atlas Discovery. No specific C-suite title published in the reviewed primary sources.

Pharmacy leader described by Asepha as CPO at MercyOne and formerly CIO at Hims & Hers and CPO at Cleveland Clinic. Listed in Asepha’s joint board/advisor section; exact seat type not individually specified.

Founder and CEO listed in the company’s Y Combinator profile. Leads Atlas Discovery’s work on AI for predictive biology and authors the company’s research and partnership announcements.

Previously a software engineer at Lyft, Databricks and Uber.

Repeat founder; previously Controller at Autodesk.

Previously founded ChaosSearch. Works on distributed systems, AI infrastructure and continuous learning.

Repeat founder; previously Head of AI at Autodesk.

Kineticos Life Sciences is a Raleigh, North Carolina life-sciences growth-equity and venture investment platform with roots in strategic consulting. Its current legal investment adviser is Kineticos Life Sciences Management LLC, CRD 318515, according to its March 26, 2026 Form ADV; the associated Kineticos Ventures LLC is named as a manager and general-partner affiliate in SEC fund filings and the firm’s own team descriptions. Those related legal entities are qualified within the platform profile, rather than treated as unrelated investors or confused with Kinetic Ventures, Horizon Kinetics, Kinetic Automation or Global Kinetics Corporation. The firm invests in pharma services, life-science tools, equipment and novel therapeutics through its Disruptor, AMR Accelerator and Capital Partners strategies. Its Disruptor series has operated since 2019, targeting oncology, neurodegenerative and rare diseases; the AMR strategy addresses antimicrobial resistance. Relevant portfolio exposure includes neuro42’s portable brain MRI, robotics and AI platform, Promaxo’s modular MRI systems and Amylyx’s neurodegenerative therapeutics. Published portfolio descriptions do not establish individual advisers’ cash investments. The current public directory lists eight core investment professionals, nine venture and operating partners and ten strategic advisers; external career titles are published background rather than independently asserted current corporate appointments. Disruptor Fund II closed exactly USD57.3 million in committed capital, announced November 17, 2023; the headline’s approximately USD60 million is rounded. Other fund/SPV gross asset values, offering targets and company financing amounts are not reported as fund closing sizes.

Feldera develops an incremental view maintenance engine that continuously updates SQL query results as underlying data changes. Built on the DBSP research framework, it computes changes to results instead of repeatedly rerunning batch jobs over entire datasets, supporting complex queries across streaming and historical data. Enterprises use it to keep AI context, authorization decisions, fraud detection, logistics and analytics current while reducing repeated data processing. The company supplies its engine and data pipeline infrastructure with lakehouse integrations and is developing a managed service.

Kepler Communications builds and operates satellite infrastructure that relays data between spacecraft and Earth in real time. Its vertically integrated Toronto operation designs, manufactures and deploys an optical communications constellation whose satellites serve as internet exchange points in orbit, using compatible inter-satellite links and network protocols. Alongside connectivity, Kepler offers hosted payload capacity and on-orbit compute to help satellite operators process and move mission data. Its operational optical relay network began with a ten-satellite ring launched in January 2026, building on earlier radio-frequency satellites and optical pathfinder demonstrations.

Marketing leader developing integrated communications strategies and brand awareness, with experience building and leading marketing teams.

Customer-facing engineer helping design and scale data pipelines, with experience in data engineering, orchestration and cloud architecture.

Commercial leader expanding adoption of Kepler’s in-orbit communications services; previously held leadership roles at Planet Labs, HawkEye 360 and Phase Four.

Open vSwitch and OVN founder and longtime developer, formerly a founding engineer at Nicira and then VMware; earned a Stanford PhD.

Leads Kepler’s U.S. government and commercial operations, with experience across space, defense, intelligence and technology.

Engineering executive previously at Cruise, Virgin Hyperloop One, Google X and Karma Automotive, bringing autonomous systems and mobility experience.

Financial executive supporting technology-company growth, fundraising, acquisitions and operational management.

Operations leader building processes for company growth, with earlier operations and marketing experience at Microsoft and Booking.com.

Full-stack engineer experienced in automotive interfaces, games, blockchain and web applications; earned a computer science master’s at Odesa Polytechnic.

Operating systems and concurrency researcher previously at VMware and ETH Zurich, where he earned his PhD.

Sales leader building Feldera’s go-to-market organization, with previous roles at Snowflake, Opaque Systems and Spectro Cloud.

Human resources leader overseeing organizational strategy, growth, effectiveness and retention, with more than 25 years of experience.

Commercial operations leader aligning sales, customer solutions and delivery while managing complex programs and market expansion.

Infrastructure engineer working on CI/CD, Kubernetes, cloud operations, releases and Kafka integrations; holds a computer science master’s degree.

Distributed systems researcher previously at VMware, where he worked on database-inspired cluster management and formal methods; earned a TU Berlin PhD.

DBSP co-creator with experience in databases, kernels, compilers, networking and formal methods; worked at VMware and research institutions; earned a UNSW PhD.

Information security leader working on governance, compliance, risk and operations, with experience across ISO, SOC2 and NIST frameworks.

DBSP co-creator and systems researcher with experience at VMware, Barefoot Networks and Microsoft; earned a Carnegie Mellon PhD.

Co-founder leading Kepler’s development of communications infrastructure in orbit and its expansion as a satellite operator.

Finance leader experienced in accounting, treasury, planning and analysis, supporting startups as their financial operations scale.

Software engineer focused on databases and data infrastructure, published on Feldera’s current engineering team.

Legal executive combining engineering and legal experience across telecommunications, technology contracts and intellectual property.

Software and systems engineer from India, published on Feldera’s current engineering team.

Product marketer with startup positioning and go-to-market experience at Hopin, CloudBees and Anomalo.

Systems engineer working on Rust connectors and platform infrastructure, with experience in compilers, Linux, embedded hardware and high-frequency trading.

neuro42, Inc. is a San Francisco medical-technology company developing portable low-field magnetic resonance imaging, artificial intelligence and robotic guidance for neurological diagnosis and image-guided brain interventions. Its diagnostic MRI platform is FDA 510(k) cleared for neuroimaging; its interventional module is seeking regulatory clearance, so clearance is not asserted for the entire robotic platform. The company licenses MRI technology developed at Massachusetts General Hospital and describes more than 40 patents supporting its platform. Its published leadership and scientific/clinical advisors are recorded with source-qualified historical appointments where its directories differ. Financing records distinguish closed equity rounds, undisclosed personal investments and later offering disclosures under review.

Abhay Sanan is published by neuro42 as Advisor. The company describes this professional background: Neurosurgeon, Center for Neurosciences, Tucson. External institution titles are directory background rather than independently verified new employment appointments.

Abhita Batra is published by neuro42 as Chief Strategy Officer. This role is listed in the current company leadership directory.

Amit Vohra is published by neuro42 as President & CEO. This role is listed in the current company leadership directory. Promaxo also publishes him as its Chief Executive Officer; its March 2026 holding-company filing identifies him as a director.

Amrith Jamoona is published by neuro42 as Advisor. The company describes this professional background: Neurosurgeon, Sutter Medical Center, Sacramento. External institution titles are directory background rather than independently verified new employment appointments.

Ben Inglis is published by neuro42 as Advisor. The company describes this professional background: Manager & Physicist, Brain Imaging Center, UC Berkeley. External institution titles are directory background rather than independently verified new employment appointments.

Clarissa Cooley is published by neuro42 as Advisor. The company describes this professional background: Radiology Instructor, Harvard & Research Staff, MGH. External institution titles are directory background rather than independently verified new employment appointments.

Erika Petersen is published by neuro42 as Advisor. The company describes this professional background: Director of Functional and Restorative Neurosurgery, UAMS Health. External institution titles are directory background rather than independently verified new employment appointments.

Physician and surgical-robotics entrepreneur who co-founded Intuitive Surgical and Auris Health. neuro42's October 2023 issuer announcement identifies him as a founding partner of Sonder Capital and confirms a direct personal investment and strategic-advisor appointment. The investment is attributed personally; no investment by Sonder, Intuitive or Johnson & Johnson is inferred.

Haidong Peng is published by neuro42 as Senior VP of MRI. This role is listed in the current company leadership directory.

Heather Spader is published by neuro42 as Advisor. The company describes this professional background: Associate Professor of Neurosurgery & Pediatric Neurosurgery Division Chief, University of New Mexico. External institution titles are directory background rather than independently verified new employment appointments.

James Kramer is published by neuro42 as Senior VP of Robotics. An earlier non-www company directory identifies the robotics role; the current www directory omits this card and continued appointment is unverified.

Jason Stockmann is published by neuro42 as Advisor. The company describes this professional background: Asst. Professor of Radiology, Harvard & Research Staff, MGH. External institution titles are directory background rather than independently verified new employment appointments.

Entrepreneur and personal deep-technology investor. neuro42's July 2021 Series A issuer announcement names Krishna R. Bhupal as an angel participant. Its October 2023 announcement appoints him to the board and describes investment interests in energy, hospitality, retail, real estate and medtech; continued board status is not independently established by the current team directory.

Lawrence Wald is published by neuro42 as Advisor. The company describes this professional background: Professor of Radiology, Harvard & Biophysicist, MGH. External institution titles are directory background rather than independently verified new employment appointments.

Mark D’Esposito is published by neuro42 as Advisor. The company describes this professional background: Professor of Neuroscience & Psychology, UC Berkeley. External institution titles are directory background rather than independently verified new employment appointments.

Michael Lawton is published by neuro42 as Advisor. The company describes this professional background: President, CEO & Chair of Neurosurgery, BNI. External institution titles are directory background rather than independently verified new employment appointments.

Nikhil Sadhwani is published by neuro42 as Chief Development Officer. This role is listed in the current company leadership directory.

P. David Adelson is published by neuro42 as Advisor. The company describes this professional background: Executive Director, WVU Medicine Children's Neuroscience Center of Excellence. External institution titles are directory background rather than independently verified new employment appointments.

Personal angel investor named in neuro42's July 2021 closed Series A announcement. The issuer does not disclose his individual ticket or provide a biography sufficient to identify unrelated same-name professionals.

Vishwa Trivedi is a Senior Associate at Zynext Ventures. Its biography describes more than five years of experience in medtech and SaaS mergers and acquisitions, advising boutique firms on sell-side and buy-side transactions.

Mitesh Shah, CFA, is a Principal at Zynext Ventures. Its biography describes more than fifteen years of healthcare equity research, IPO and follow-on placement, and valuation of public and private companies.

Jay Kothari is a Director of Zynext Ventures. Its biography also identifies him as Senior Vice President of Business Development at Zydus Pharmaceuticals USA, with more than two decades of global pharmaceutical business development and commercial experience.

Santosh Iyer is a venture partner at Heinz Ventures. His manager biography describes computer vision, AI, advanced imaging and robotics advisory experience at Starscape Consulting and healthcare workforce-development leadership at Moonshot. He holds an MBA from Harvard and biomedical-engineering and engineering-science degrees from the University of Toronto.

Zynext Ventures is the corporate venture investment arm of Zydus Lifesciences, based in Pennington, New Jersey. It invests in seed, early-stage and growth-stage healthcare companies, including preclinical and clinical therapeutics, medical devices, imaging and digital technologies. Its published approach uses data analytics and AI to evaluate opportunities and offers access to Zydus’s pharmaceutical, regulatory and commercial capabilities. Published portfolio investments include neuro42, developing portable MRI and robotics for neurological imaging and interventions; Promaxo, developing low-field MRI and minimally invasive robotics; Feldan Therapeutics, developing intracellular drug delivery; Illexcor Therapeutics, developing oral sickle cell therapies; and Agenus, developing cancer immunotherapies. SEC filings identify Zynext Ventures USA LLC as a Delaware investment vehicle wholly owned by Singapore’s Zynext Ventures Pte Ltd, which is wholly owned by Zydus Lifesciences. These legal vehicles are represented under one venture-arm identity; neither the parent’s market capitalization nor individual portfolio investments constitute a disclosed raised venture fund.

Nishant Shah is a venture partner at Heinz Ventures providing clinical diligence. His own manager biography describes anesthesiology and acute-pain medicine practice, University of Illinois clinical teaching, medical-direction experience, and cofounding Rapid Recovery Pathways. He holds an MD and psychology degree from University of Illinois.

Lori Dugan is a venture partner at Heinz Ventures with healthcare market-access, reimbursement, payer strategy and evidence-generation experience. Her manager biography lists work at Smith+Nephew, HeartWare/Medtronic, Johnson & Johnson and Smiths Medical. She holds a business-administration degree from California State University Fullerton.

Larry Liu is a venture partner at Heinz Ventures focused on deals and diligence. His manager biography describes regulated medical devices, surgical robotics, digital health and AI software experience at Stryker, Horizon Medical Device Consulting, Verb Surgical/Johnson & Johnson and Medable. He holds a bioengineering degree from UC Berkeley and completed Stanford Ignite.

Heinz Ventures, LLC is an operator-led early-stage medical-technology investment manager based in Memphis, Tennessee. Eric S. Heinz founded the advisory business in 2015 and the firm launched its investment fund in 2024. It focuses on pre-seed and seed investments in regulated medical devices, particularly U.S. companies in the Midwest and Southeast, combining capital with clinical, regulatory, product-development, commercialization and transaction experience. Its neurotechnology portfolio includes hydrocephalus-device developer Madison Scientific and noninvasive intracranial-pressure monitoring developer CranioSense. Current publicly named leadership comprises Eric Heinz and venture partners Larry Liu, Lori Dugan, Nishant Shah and Santosh Iyer. SEC filings distinguish legal manager Heinz Ventures, LLC from Heinz Ventures Fund I GP, LLC and Delaware fund Heinz Ventures Fund I, LP. Final fund close size and date are not publicly verified.

Graeme Clark is the Bionics Institute’s founder (1986). The affiliation is explicitly historical.

Hamish MacDougall joined the Bionics Institute to develop extended-reality devices for neurological diagnosis. His official interview describes remote eye-movement assessments and earlier work including NASA. The proposed device is a research project; broad clinical availability is not inferred.

John Stanhope is the Bionics Institute’s former chair (2016–2025; historical). The affiliation is explicitly historical.

Neil Balme is an AFL leader and publicly named Bionics Institute ambassador supporting epilepsy awareness and neurological research. This is an ambassador affiliation rather than employment, clinical practice or a personal investment.

Rick Goldberg is named as industry advisory committee member (published news affiliation; current tenure unconfirmed) by the Bionics Institute. This is a source-qualified advisory or volunteer committee affiliation, not an inferred employee position.

Stephanie Tan is named as industry advisory committee member (published news affiliation; current tenure unconfirmed) by the Bionics Institute. This is a source-qualified advisory or volunteer committee affiliation, not an inferred employee position.

Caroline Chernov is named as fundraising committee member (2024–25 report) by the Bionics Institute. This is a source-qualified advisory or volunteer committee affiliation, not an inferred employee position.

Ed Phillips is named as young bionics committee member (2024–25 report) by the Bionics Institute. This is a source-qualified advisory or volunteer committee affiliation, not an inferred employee position.

Emily Jarman is named as young bionics committee member (2024–25 report) by the Bionics Institute. This is a source-qualified advisory or volunteer committee affiliation, not an inferred employee position.

Ethan Duff is named as young bionics committee member (2024–25 report) by the Bionics Institute. This is a source-qualified advisory or volunteer committee affiliation, not an inferred employee position.

Ilan Davidoff is named as young bionics committee member (2024–25 report) by the Bionics Institute. This is a source-qualified advisory or volunteer committee affiliation, not an inferred employee position.

Isabella Gaudry is named as young bionics committee member (2024–25 report) by the Bionics Institute. This is a source-qualified advisory or volunteer committee affiliation, not an inferred employee position.

Jaala Pulford is named as industry advisory committee member (published news affiliation; current tenure unconfirmed) by the Bionics Institute. This is a source-qualified advisory or volunteer committee affiliation, not an inferred employee position.

Jed Bertalli is named as fundraising committee member (2024–25 report) by the Bionics Institute. This is a source-qualified advisory or volunteer committee affiliation, not an inferred employee position.

Jeremy Ungar is named as fundraising committee member (2024–25 report) by the Bionics Institute. This is a source-qualified advisory or volunteer committee affiliation, not an inferred employee position.

Jim Hayman is named as fundraising committee member (2024–25 report) by the Bionics Institute. This is a source-qualified advisory or volunteer committee affiliation, not an inferred employee position.

Kaitlin Beattie is named as young bionics committee member (2024–25 report) by the Bionics Institute. This is a source-qualified advisory or volunteer committee affiliation, not an inferred employee position.

Kunal Rastogi is named as fundraising committee member (2024–25 report) by the Bionics Institute. This is a source-qualified advisory or volunteer committee affiliation, not an inferred employee position.

Ned Gill is named as young bionics committee member (2024–25 report) by the Bionics Institute. This is a source-qualified advisory or volunteer committee affiliation, not an inferred employee position.

Tim Luscombe is named as young bionics committee member (2024–25 report) by the Bionics Institute. This is a source-qualified advisory or volunteer committee affiliation, not an inferred employee position.

Will Anderson is named as young bionics committee member (2024–25 report) by the Bionics Institute. This is a source-qualified advisory or volunteer committee affiliation, not an inferred employee position.

Alan Robertson is named as industry advisory committee member (2024–25 report) by the Bionics Institute. This is a source-qualified advisory or volunteer committee affiliation, not an inferred employee position.

Andrew Campitelli is named as industry advisory committee member (2024–25 report) by the Bionics Institute. This is a source-qualified advisory or volunteer committee affiliation, not an inferred employee position.

Andrew Nash is named as industry advisory committee member (2024–25 report) by the Bionics Institute. This is a source-qualified advisory or volunteer committee affiliation, not an inferred employee position.

Brandon Alter is named as industry advisory committee member (2024–25 report) by the Bionics Institute. This is a source-qualified advisory or volunteer committee affiliation, not an inferred employee position.

Evange Romas is publicly named by the Bionics Institute as clinical collaborator. A/Prof Romas, an Honorary Fellow at the Bionics Institute, is a rheumatologist with a full clinical workload and over 25 years’ experience as an educator and clinical researcher in the field As the Director of Rheumatology at St Vincent’s Hospital Melbourne, A/Prof Romas brings substantial clinical experience and expertise to the team. With a personal cohort of 1000 private patients with rheumatoid arthritis, A/Prof Romas will ensure that our bionic therapy is clinically relevant and useful to patients. A/Prof Romas also holds the appointment of Associate Professor and Principal Fellow at the University of Melbourne.

Ingrid Williams is named as industry advisory committee member (2024–25 report) by the Bionics Institute. This is a source-qualified advisory or volunteer committee affiliation, not an inferred employee position.

Jagdeep Singh is named as industry advisory committee member (2024–25 report) by the Bionics Institute. This is a source-qualified advisory or volunteer committee affiliation, not an inferred employee position.

Michael Kohn is named as industry advisory committee member (2024–25 report) by the Bionics Institute. This is a source-qualified advisory or volunteer committee affiliation, not an inferred employee position.

Michael Stilwell is named as fundraising committee chair (2024–25 report) by the Bionics Institute. This is a source-qualified advisory or volunteer committee affiliation, not an inferred employee position.

Pamela Batrouney is named as fundraising committee member (2024–25 report) by the Bionics Institute. This is a source-qualified advisory or volunteer committee affiliation, not an inferred employee position.

Penina Ponger is publicly named by the Bionics Institute as clinical collaborator. Penina is a clinical fellow at the Balance Disorders & Ataxia Service (BDAS) at the Royal Victorian Eye & Ear Hospital and honorary research fellow at the Bionics Institute. Academic and Professional Background: Dr. Ponger is a senior neurologist and geneticist specialising in movement disorders and neurogenetics. She earned her MD from Tel Aviv University, graduating magna cum laude in Medical Sciences (2005–2009). Her training includes Neurology at Hadassah Medical Center, Jerusalem (2010–2016) and a fellowship in Medical Genetics, Tel Aviv Sourasky Medical Center (2017–2021). Her past positions have included heading the Adult Neurogenetics Service and Ataxia Clinic along with site coordination of PDGENEration Research Initiative, at Tel Aviv Sourasky Medical Center. Dr.

Stephen O’Leary is publicly named by the Bionics Institute as clinical collaborator. Stephen O’Leary holds the William Gibson Chair of Otolaryngology at the University of Melbourne, and is a Senior Otolaryngologist at the Royal Victorian Eye and Ear Hospital. He obtained his PhD in 1994 under Prof Graeme Clark and has undertaken post-doctoral research at Oxford under David Moore and the University of Utrecht under Jan Veldman. Prof O’Leary’s clinical and research interests are in cochlear implantation, drug delivery to the ear and otology. His group specializes in clinical translation of experimental research and CI-related clinical research. Prof O’Leary’s special interest has been in the preservation of inner ear function during surgery on the cochlea.

Mark Cook is publicly named by the Bionics Institute as clinical collaborator. Professor Mark Cook is Director of Neurology at St Vincent’s Hospital Melbourne and Sir John Eccles Chair of Medicine at the University of Melbourne, with a concurrent appointment as Professor of Biomedical Engineering. Mark is an internationally recognised neurologist with a primary clinical and research focus on epilepsy, particularly the management of complex and drug-resistant disease. He completed specialist neurological training in Melbourne, followed by doctoral research at the National Hospital for Neurology and Neurosurgery, Queen Square, London, before returning to Melbourne to build a program integrating advanced neuroimaging, neurophysiology, and clinical epilepsy care.

Peter De Cruz is publicly named by the Bionics Institute as clinical collaborator. Professor Peter De Cruz is one of Australia’s leading inflammatory bowel disease (IBD) specialists; he is the Director of the IBD service at the Austin Hospital and a Senior lecturer at the University of Melbourne. Professor De Cruz has been highly impressed by the depth and breadth of talent within the Bionics Institute and is excited about the prospect of turning dreams into reality. Research project > I feel incredibly privileged to be part of such a fantastic team that has taken a proof-of-concept from pre-clinical research, to a world first-in-human clinical trial to assist Crohn’s disease patients.

Robert Briggs is publicly named by the Bionics Institute as clinical collaborator. No additional background or appointment date is inferred.

Alex Craven is publicly named by the Bionics Institute as clinical collaborator. Dr Alex Craven is a specialist upper gastrointestinal (UGI) surgeon with expertise in advanced laparoscopy, complex foregut surgery, and the development of novel surgical technologies. His clinical and research work focuses on minimally invasive approaches to oesophageal and gastric disease, the development of implantable devices, and improving functional outcomes following UGI interventions. Dr Craven trained at Austin Health and Northern Health through the Royal Australasian College of Surgeons before completing post-fellowship training in upper GI surgery.

David Proud is publicly named by the Bionics Institute as clinical collaborator. Mr David Proud is a Colorectal and General Surgeon. He holds current appointments as the Acting Head of Unit – Colorectal Surgery, and Supervisor of General Surgery training at the Austin Hospital. Mr Proud received his Medical Degree from Monash University and trained in General Surgery at Alfred Health. He is a Fellow of the Royal Australasian College of Surgeons, and a member of the Colorectal Surgery Society of Australia and New Zealand (CSSANZ). After completing his Australian training, Mr Proud undertook prestigious international fellowships in Colorectal Surgery at St Vincent’s University Hospital in Dublin and at Austin Health, before joining the Colorectal Surgery department as a consultant surgeon.

Shereen Oon is publicly named by the Bionics Institute as clinical collaborator. A/Prof Shereen Oon, MBBS (Hons), BMedSci, FRACP, PhD, is the Director of Rheumatology at St. Vincent’s Hospital, and a consultant rheumatologist at The Royal Melbourne Hospital, The Royal Victorian Eye and Ear Hospital and Eastern Health. She has experience in basic science, clinical research and clinical trial research in rheumatology.  She is an Honorary Research Fellow at the Bionics Institute and an Honorary Associate Professor at the University of Melbourne. A/Prof Oon is currently involved in the Vagus Nerve Stimulation research program at Bionics Institute, as Coordinating Principal Investigator of the first clinical trial of abdominal VNS in Rheumatoid Arthritis. Research project

Christopher Hart is publicly named by the Bionics Institute as clinical collaborator. Dr Christopher Hart is a Medical Oncologist who holds appointments at St Vincent’s Private Hospital and St Vincent’s Public Hospital in Melbourne. Dr Hart graduated from the University of Melbourne in 2005 with an MBBS, BA, and BSc, later completing his specialist oncology training in Melbourne in 2013 to become a Fellow of the Royal Australasian College of Physicians (FRACP). Following his local training, he undertook a two-year international translational research fellowship in breast cancer at Prato Hospital in Italy before returning to Melbourne in 2016. His main clinical and research area of interest is in breast cancer, with additional interest in head and neck, and central nervous system (CNS) cancers.

Paul Fitzgerald is publicly named by the Bionics Institute as clinical collaborator. No additional background or appointment date is inferred.

Sarah Osborn is publicly named by the Bionics Institute as senior clinical research specialist. Sarah Osborn joined the Bionics Institute in 2023 as a Senior Clinical Research Specialist, supporting and facilitating clinical research projects. Sarah is a member of the Clinical Research Support Team (CREST). Sarah has worked in the clinical research industry for the majority of her career, having held positions at a Victorian Public Hospital, a major international Contract Research Organisation (CRO) and at other Medical Research Institutes. She has had involvement in investigator-initiated, collaborative group and commercially-sponsored clinical research projects and trials across all phases. Sarah holds a Bachelor of Science degree with Honours from Monash University and a Graduate Certificate in Clinical Research from the University of Melbourne.

Chris Weaver is publicly named by the Bionics Institute as senior development manager. Chris Weaver joined the Bionics Institute in 2026 as Senior Development Manager. He has spent 15 years working in professional fundraising, with a broad spectrum of experience across communications, marketing and development. He previously worked as a major gift fundraiser in school education, where he secured major gifts from individuals, groups, trusts and foundations. Prior to this, Chris developed cases for support for the University of Melbourne during the first decade of the University’s highly successful ‘Believe’ campaign. This has given him a strong understanding of the needs of researchers working in complex interdisciplinary environments.

Kylie O’Neill is publicly named by the Bionics Institute as facilities operations manager. Kylie graduated with a Bachelor of Applied Science in Biotechnology from Queensland University of Technology in 2004 and a Master of Science in Forensic Science from Griffith University in 2008. She started her career in a plant molecular genetics research laboratory at the University of Queensland in 2005 and progressed into forensic DNA profiling for a multitude of species including humans, bovine, ovine and canine. Prior to working at Bionics she was a Senior Scientist undertaking work in medical genetic testing and animal genetics. Her role at the institute involves managing the laboratory, facilities and OHS but more importantly, engineer wrangling.

Lyndal Borrell is publicly named by the Bionics Institute as quality and research governance manager. Lyndal Borrell is our Quality and Research Governance Manager. After completing her PhD in Microbiology in 2004, she realized her passions lie with writing, and she enjoys reading scientific articles. She worked as a medical writer and pharmacovigilance associate before joining the Bionics Institute in 2016 as Research Governance Officer. In 2019, she became Quality Manager and she still enjoys reading scientific articles.

Anu Sabu is publicly named by the Bionics Institute as research fellow. No additional background or appointment date is inferred.

Daniel Williams-Wynn is publicly named by the Bionics Institute as research engineer. Daniel Williams-Wynn is a Research Engineer at the Bionics Institute. He completed undergraduate studies in Biomedical Engineering at RMIT in 2018 and joined the Bionics Institute in 2022, working as part of the Engineering Team’s Research Support capability. Having supported many different projects during his time at the Bionics Institute, Daniel has developed a wide range of engineering skills including electronics and circuit design, mechanical design and manufacture, software engineering, and electrode design. .

Peter Seligman is publicly named by the Bionics Institute as senior scientific mentor. Peter Seligman is an honorary Professor of the University of Melbourne, a biomedical engineer at the Bionics Institute, and an associate of the Melbourne Energy Institute. Peter was a key member of the team that developed the Melbourne/Cochlear multiple-channel cochlear implant. He worked in the field for 30 years and was particularly responsible for the development and improvement of speech processors. In 1979 he designed the first portable Speech Processor for the University of Melbourne device. He joined Cochlear Ltd (Nucleus) in 1983 and was instrumental in speech processor miniaturisation and improvement, including the development of custom microchips to implement new speech processing strategies.

Amy Morley is publicly named by the Bionics Institute as senior research assistant. No additional background or appointment date is inferred.

Oscar Murphy is publicly named by the Bionics Institute as senior clinical research fellow. No additional background or appointment date is inferred. Oscar Murphy is a named co-inventor of CogTx’s personalized TMS software, with Kate Hoy and David Hill; this scientific inventor attribution does not establish a separate executive or board appointment.

Tomoko Hyakumura is publicly named by the Bionics Institute as research fellow. Tomoko is a postdoctoral researcher at Bionics Institute. Prior to joining Bionics Institute, she completed her PhD at the University of Melbourne investigating the potential of regenerating the auditory nerve using stem cells. She joined Bionics Institute in 2018, taking part in the study of vagus nerve stimulation for treatment of inflammatory bowel disease. Dr Hyakumura gained further preclinical research experience studying a range of unique neural signals from both the central and peripheral nervous system utilising novel electrode coating materials in collaboration with researchers at University of NSW.

David Hill is publicly named by the Bionics Institute as research engineer. David holds a Bachelor of Biomedical Engineering with honours (RMIT University, 2017), having completed an internship at Bionics Institute where he developed processes for the assembly and testing of sealed implantable electronic devices. From 2018 to 2022, David was part of the “Just-in-time Bone Tumour Implants” Innovative Manufacturing CRC project, completing a Ph.D. in Surgical Robotics (RMIT University, 2022). The focus of his thesis was on the development of novel tools and algorithms to optimise and automate the pre-operative planning and removal of bone tumours. Collaborating with industry and clinicians, his research integrated surgical robotics with additive manufacturing, resulting in two patents on automated pre-operative planning tools. David Hill is a named co-inventor of CogTx’s MRI-based targeting software for personalized TMS, with Kate Hoy and Oscar Murphy; no additional company executive title is inferred.

Demi Gao is publicly named by the Bionics Institute as senior research scientist. Dr Demi X. Gao is a Senior Research Scientist at the Bionics Institute and a Passe and Williams Foundation Mid-Career Fellow. Demi’s research program spans the fields of neural engineering, biomedical engineering, brain imaging and machine learning to understanding human hearing system, including developing techniques for hearing loss diagnosis and optimising the performance of next-generation cochlear implants. Demi possesses a broad multidisciplinary skill set with a diverse research background encompassing information technology, neural engineering, and bio-signal processing. Since completing her PhD in December 2016, Demi has been awarded over $ 1 Million research fundings as a solo investigator.

Yingjie Hu is publicly named by the Bionics Institute as research and development engineer. Dr Yingjie Hu joined the Bionics Institute as a Research and Development Engineer after completing her PhD in Chemical and biomolecular engineering at the University of Melbourne. Her expertise lies in nanoparticle engineering and protein-nanoparticle interactions. Currently she is part of the hearing therapeutic team led by A/professor Andrew Wise.

Jamal Esmaelpoor is publicly named by the Bionics Institute as researcher and engineer. Dr Jamal Esmaelpoor is a Biomedical Signal Engineer and Data Scientist at the Bionics Institute, working at the intersection of engineering, neuroscience, and clinical research to translate complex biomedical data into meaningful clinical insights. He completed his PhD at the University of Melbourne in 2026 within the Medical Bionics Department. His doctoral research focused on identifying reliable brain-based predictors of cochlear implant outcomes using functional near-infrared spectroscopy (fNIRS). His work demonstrated how patterns of brain network organisation and dynamic functional connectivity can predict speech understanding outcomes in cochlear implant recipients, contributing to improved patient selection and more personalised clinical care.

Mary Ardren is publicly named by the Bionics Institute as post-doctoral research fellow. Mary’s background is in neurophysiology, completing her PhD at the Eccles Institute of Neuroscience at the Australian National University in 2023. Her expertise lies in electrophysiology, glutamatergic neurotransmission and olfactory neuroscience. Currently, she works with A/Prof Rachael Richardson to study how optogenetics can be used to modulate activity in peripheral nerves.

Michelle Bravo is publicly named by the Bionics Institute as researcher and engineer. Michelle holds a Bachelor of Biomedical Engineering with Honours (Swinburne University of Technology, 2017), and is a member of our tinnitus research team. Michelle is working to establish an objective measure of tinnitus by recording brain activity, alongside Dr Mehrnaz Shoushtarian. With experience in design, implementation and data collection requirements of clinical trials, Michelle also provides engineering support for a number of our other research projects. This includes the application of abdominal vagus nerve stimulation for Crohn’s disease and rheumatoid arthritis, and the application of non-invasive stimulation to the hands or feet to alleviate motor symptoms associated with Parkinson’s disease.

Ella Trang is publicly named by the Bionics Institute as histology and in-vitro team leader. Ella completed her Bachelor of Biomedical Science, with Honours, in 2015 at Monash University and since 2016 has been working at the Bionics Institute. Currently the Histology and In-Vitro Team Leader, Ella specialises in histological processing and image analysis. She is also currently completing a PhD in Medical Bionics at the University of Melbourne. Her research is focused on investigating the electrode-tissue interface through optimised three-dimensional visualisation approaches.

Jenny Zhou is publicly named by the Bionics Institute as electrode fabrication lead. Jenny received her Master of Telecommunications Engineering from the University of New South Wales in 2004 and has worked as a consultant for the International Business Network and GTH Rentals in Sydney. Jenny joined the Institute in 2015 and has worked extensively across most projects. She’s mainly focus on fabricating high quality custom-made implantable devices.

Nara Liu is publicly named by the Bionics Institute as post-doctoral research fellow. Nara Liu is a Research Engineer at the Bionics Institute, completing her PhD at the Department of Biomedical Engineering at the University of Melbourne in 2024 Dr. Nara Liu is a postdoctoral researcher specialising in neuroengineering and computational neuroscience. Her doctoral research focused on understanding and optimising endovascular stimulation of peripheral nerves through the integration of computational modelling, pre-clinical experiments, and biosignal analysis. At the Bionics Institute, Nara works with A/Prof Sophie Payne and Dr. Tomoko Hyakumura to develop computational models of biological systems that investigate how vagus nerve stimulation parameters affect therapeutic outcomes in seizure control for individuals with drug-resistant epilepsy.

Alex Thompson is publicly named by the Bionics Institute as engineering team leader. Dr Alex Thompson leads our Engineering Capability, a critical unit with 6 engineers who provide engineering and product development expertise to help advance research ideas into products that help patients. He has over 15 years of experience in various biomedical engineering specialities, including neuromodulation, biomedical device development, data analysis, advanced optical neural stimulation and modelling. His work has resulted in over 25 publications and attracted $4.1M in funding. Alex obtained his PhD at Swinburne University (2010 – 2013), then moved to the University of St Andrew (2014-2016) as a Research Fellow before joining the Bionics Institute in 2017.

Peta Grigsby is publicly named by the Bionics Institute as animal research team leader. Associate Professor Peta Grigsby leads our Animal Research Team (ART), a key capability pillar within the Bionics Institute. ART provide husbandry, surgical and functioning testing for all the pre-clinical animal models used at the Bionics Institute. Peta is passionate about ensuring the expert surgical support provided by the team is at a world leading standard and is continually looking for ways to develop the team’s expertise and capabilities. With over 20 years of experience developing animal models for research working with multiple species (e.g., monkeys, sheep, cats, guinea pigs and rodents), Associate Professor Grigsby’s diverse research background has provided her with the skills and knowledge needed for complex research projects.

Sally Herring is publicly named by the Bionics Institute as clinical research support team leader. Dr Sally Herring is the Clinical Research Support Team Leader at the Bionics Institute, and leads the Institute’s Consumer and Community Involvement (CCI) program. Since joining the Bionics Institute in 2022, Sally has supported the conduct and implementation of clinical trials across the Institute in a research governance role. As lead of the CCI program, Sally facilitates and supports connections between researchers and people with lived experience of the conditions being researched. Comprised of a CCI Coordinator, researchers, advocacy groups and lived experience experts, this program aims to integrate consumer expertise into all types and stages of research at Bionics Institute.

Andrew Wise is publicly named by the Bionics Institute as head of hearing therapeutics research program. A/Prof Wise graduated from Monash University (PhD) in 2002 where he undertook research in neuroscience. He was recruited to the Bionic Ear Institute (2001-2003) as a post-doctoral research Fellow focusing on auditory neuroscience. A/Prof Wise moved to Bristol UK where he took up post-doctoral position (2003-2006) before returning to Melbourne in 2006 to continue research at the Bionics Institute. His  research focuses on understanding hearing impairment and developing therapeutic technology to treat it. A/Prof Wise, his research team and collaborators have developed a new way to deliver therapeutic drugs to the inner ear to treat hearing impairment.

David Szmulewicz is publicly named by the Bionics Institute as research leader — movement and balance disorders. David is an Associate Professor and Principal research fellow at the Bionics Institute. He is a neurologist, neuro-otologist and translational researcher interested in diseases which interfere with normal human movement, which include the cerebellar ataxias. He is the founding head of the Balance Disorders & Ataxia Service (BDAS) at the Royal Victorian Eye & Ear Hospital, the Fragile X-Associated Tremor Ataxia (FXTAS) Clinic. He consults in the Monash Health Friedreich Ataxia clinic and the Machado-Joseph Disease Foundation Ataxia Clinic (Northern Territory), an honorary neurologist at St Vincent’s Hospital, Melbourne and a lecturer at Melbourne University. David’s clinical and research focus are disorders of the cerebellum, vestibular and somatosensory systems.

Mehrnaz Shoushtarian is publicly named by the Bionics Institute as project leader — tinnitus imaging. Mehrnaz Shoushtarian graduated with a PhD in Biomedical Engineering from Monash University. She has worked in both research (Monash Health, Eastern Health) and industry (Cortical Dynamics, Hearing Cooperative Research Centre). Associate Professor Shoushtarian’s research has focused on measurement and processing of physiological signals using conventional and novel recording techniques and use of research outcomes for development and commercialisation of medical devices. Her main focus at the Bionics Institute involves using functional near-infrared spectroscopy (fNIRS) and other physiological measures, to develop objective measures of tinnitus.

Kate Hoy is publicly named by the Bionics Institute as head of cognitive therapeutics research program. Professor Kate Hoy (she/her) is head of the Cognitive Therapeutics Research Program at the Bionics Institute. Professor Hoy is a leading clinical researcher and has been awarded three sequential NHMRC Fellowships; an NHMRC excellence award (Top Ranked CDF); and a 2017 Victorian Telstra Business Women’s Award. She is a practicing neuropsychologist and is Director of The Neuropsychology Practice. Her vision is to transform the existing therapeutic landscape for cognitive disorders by developing, for the first time, truly effective therapies. Over more than 18 years, Professor Hoy has built an internationally unique program of clinical research investigating non-invasive brain stimulation for the treatment of cognitive disorders. Kate Hoy is a co-inventor of CogTx’s MRI-based software for personalized transcranial magnetic stimulation, alongside Oscar Murphy and David Hill. CogTx is commercializing Bionics Institute research; its Alzheimer’s application remains investigational.

Rachael Richardson is publicly named by the Bionics Institute as head of optogenetics research program. Professor Rachael Richardson is a Principal Research Fellow at the Bionics Institute, and Professor in the Medical Bionics Department, University of Melbourne. Rachael’s scientific career, spanning more than 25 years, has centered on developing innovative and translational solutions for neurological conditions. She currently leads a multi-disciplinary team researching precise neuromodulation technology in the auditory, visual, peripheral, and central nervous systems. A major focus of her work is a technology known as optogenetics, which enables light to be used for precise and selective neuromodulation. Rachael is an inventor of a combined stimulation strategy (patent filed internationally) that uses both optogenetics and electrical stimulation.

Sophie Payne is publicly named by the Bionics Institute as head of vagus nerve stimulation centre of excellence. Sophie is Head of Vagus Nerve Stimulation Centre of Excellence (VNS CoE) at the Bionics Institute and is a Principal Research Fellow (honorary) at the University of Melbourne. She completed her PhD in neuroscience at the University of Western Australia (2010-2013), then moved to the University of Melbourne (2013-2015) as a Research Fellow and later to the Bionics Institute (2015-present). Using electricity to alter the activity of the vagus nerve has demonstrated success in the treatment of many human diseases and has led to the establishment of the Vagus Nerve Stimulation Centre of Excellence (VNS CoE).

Sheridan Laing is publicly named by the Bionics Institute as head of research operations. Dr Sheridan Laing is Head of Research Operations and commenced at the Institute in 2021. PhD studies in Biomedical Engineering at the University of Melbourne and her career spans 12 years of successful delivery of applied and translational biomedical engineering research programs in academic, government and not-for-profit organisations. Prior to joining the Institute, she spent 9 years with the Defence Science and Technology group, undertaking and managing applied biomedical engineering research programs. Sheridan brings this experience and expertise to the Bionics Institute to provide project and operational support to the research activities across the Institute and to the Chief Technology Officer.

Simon Richardson is publicly named by the Bionics Institute as head of information technology. Simon Richardson was appointed as the Head of Information Technology in 2023 to lead the IT team and grow Bionics Institute’s technology platforms and governance. Simon has a Master of Business Administration from La Trobe University and over 25 years’ experience in IT and business leadership within the Not-for-profit, health, education and food industry sectors. Simon’s health experience includes the National Heart Foundation, Royal Australian College of General Practitioners (CIO, COO), St. Vincent’s Health Australia (CTO), St. Vincent’s Hospital Melbourne (CIO), Mercy Health (GM ICT). Simon is passionate about technology and building high performing teams and within purpose-driven organisations that make a difference to the world.

Louise Kavanagh is publicly named by the Bionics Institute as head of human resources. Louise is a dedicated and values-driven HR professional with over 25 years of experience, who believes in the power of effective people strategies to unlock potential and drive organisational success. Louise joined the Bionics Institute in 2022, combining her strategic insight with her operational expertise to foster collaboration, engagement, and wellbeing across teams. Known for her results-driven approach, she has successfully led transformative cultural and organisational effectiveness initiatives that significantly boosted employee engagement, leadership capability, organisational culture, and created inclusive and high-performing workplaces.

Veena D’Souza is publicly named by the Bionics Institute as head of finance. Veena D’Souza is Head of Finance at the Bionics Institute. A registered Chartered Accountant and Certified Practising Accountant (CPA), Veena has over 30 years of experience in the field both in Australia and overseas. Veena joined the Bionics Institute in 2018 and she leads a dedicated team of CPAs and Chartered Accountants, overseeing the financial operations of the Institute, ensuring that financial strategies align with its objectives. Veena’s responsibilities extend beyond managing the finances of the Bionics Institute, to also establishing and overseeing the finances for spin-off companies set up by the Bionics Institute to commercialise medical devices for the benefit of patients. Veena’s strengths lie in running a tight ship and her passion for ensuring that every Institute dollar is spent wisely.

James Fallon is publicly named by the Bionics Institute as chief technology officer. Prof James Fallon is Chief Technology Officer at the Bionics Institute, and Head of the Medical Bionics Department, University of Melbourne. Professor Fallon’s mission is to develop devices that monitor or modulate neural activity for managing health conditions. He does this by forging expert teams of bioengineers, neuroscientists and clinicians who translate research into clinically meaningful outcomes. Professor Fallon has two decades of internationally recognized experience with in vivo electrical stimulation and recording, supported by grants totaling over $27 million and commercial research totaling over $6 million. His work has generated over 110 research publications and more than 17 patent applications, including several granted patents under license to medical technology companies.

Jo Crowston is publicly named by the Bionics Institute as head of development. As Head of Development, Jo Crowston leads fundraising and marketing at the Bionics Institute. As Head of Development at the Bionics Institute, Jo leads growth in fundraising and marketing to support groundbreaking medical device research through philanthropic and corporate giving, grants and impact investment. An experienced manager, Jo’s 35-year career spans roles across a diverse range of non-profit and government organisations, including The Prince’s Trust, VicHealth, St Vincent’s Institute, OET and AMEB. A graduate of the Chief Executive Women Leadership Program and the UK MBA in Marketing Program, Jo is a Non-Executive Director on the Board of Australian Science Innovations (ASI), which runs Maths and Science Olympiads with Federal Government funding.

Karen Campitelli is publicly named by the Bionics Institute as chief operating officer. Karen Campitelli is the Chief Operating Officer at the Bionics Institute. Karen is passionate about enabling the multi-disciplinary research teams across the Institute to translate their work into health solutions. Since joining the Bionics Institute in 2011, she has developed a strong understanding of the med tech sector and works closely with the research leaders to assist their teams in forging strong collaborative relationships with research and commercial partners. Supporting the translation of novel ideas into granted patents, she has played a key role in the successful commercialisation of several projects, from managing the intellectual property portfolio to the eventual incorporation and investment into early-stage companies.

Mike Younger is publicly named by the Bionics Institute as board director. No additional background or appointment date is inferred.

Robert Klupacs is publicly named by the Bionics Institute as chief executive officer. No additional background or appointment date is inferred.

Maureen O’Keefe is publicly named by the Bionics Institute as board director. No additional background or appointment date is inferred.

Paul Lefebvre is publicly named by the Bionics Institute as board director. No additional background or appointment date is inferred.

Sean Moore is publicly named by the Bionics Institute as board director. Sean Moore is a Partner at Deloitte, the world’s largest professional services firm built on more than 175 years service to clients in more than 150 countries and territories. At Deloitte, Sean advises leading  financial institutions on risk, technology and business transformation. Prior to Deloitte, he was a Managing Director leading global investment banks Nomura and Lehman Brothers. His international career has seen him live and work in Australia, New York, London, Zurich, Frankfurt, Singapore and Hong Kong. Sean has been supporting the Bionics Institute as a member of the Fundraising Committee through 2024.

Reza Zadno is listed by Mobia Medical (formerly MicroTransponder) as Board Member. He joined Jolt Capital as an operating partner in February 2026 after serving as chief executive of PROCEPT BioRobotics and Avedro. His Mobia board appointment was announced July 14, 2026.

Cynthia Lucchese is listed by Mobia Medical (formerly MicroTransponder) as Board Member. Her finance and governance experience includes CooperCompanies, BVI, Penske, Hillenbrand, Thoratec and Guidant.

Max Bikoff is listed by Mobia Medical (formerly MicroTransponder) as Board Member. Also identified as Maxwell Bikoff. He is a managing director at Longitude Capital, which he joined in 2016, with previous experience at Cardinal Health and Deloitte.

Prashant Rawat is listed by Mobia Medical (formerly MicroTransponder) as Chief Operating Officer. He has more than two decades of development and operating experience across neurostimulation, cardiovascular and neurovascular technologies, including Boston Scientific, Mainstay Medical and CVRx.

Swaril Mathur is listed by Mobia Medical (formerly MicroTransponder) as Vice President, Strategy and Growth. His background includes corporate strategy at Axonics and Edwards Lifesciences and Stanford Biodesign training.

Chase Leavitt is listed by Mobia Medical (formerly MicroTransponder) as General Counsel. He became general counsel and corporate secretary in February 2026; prior legal roles include Oncternal Therapeutics, Lineage Cell Therapeutics and Latham & Watkins.

Navzer Engineer is listed by Mobia Medical (formerly MicroTransponder) as Co-Founder and Chief Scientific Officer. His medical and neuroscience research background underpins the company’s paired vagus-nerve-stimulation research; he earned a neuroscience doctorate at the University of Texas at Dallas.

Bunker Curnes is listed by Mobia Medical (formerly MicroTransponder) as Chief Financial Officer. Also identified in SEC filings as Nelson Bunker Curnes. He joined the company in 2011 and became CFO in 2020, following work at HEMCO and Boston Consulting Group.

Doug Ellison is listed by Mobia Medical (formerly MicroTransponder) as Chief Commercial Officer. His medical-device commercial leadership experience includes AtriCure, SentreHEART and Cardica.

Jordan Curnes is listed by Mobia Medical (formerly MicroTransponder) as Co-Founder. He co-founded the company in 2007, following consulting experience at Huron.

Steffanie Cook is listed by Mobia Medical (formerly MicroTransponder) as Vice President, Human Resources. She previously held human-resources leadership roles at Silk Road Medical, Honeywell and Endologix.

Richard Foust is listed by Mobia Medical (formerly MicroTransponder) as President and Chief Executive Officer. He has led commercialization of medical technology at Velano Vascular, Abbott, Guidant and Analyte Health; his training includes applied physics and bioengineering.

Jennifer Dicker is publicly named by the Bionics Institute as board director. Jennifer Dicker currently serves as the Chairman of the Steritech Pty Ltd advisory board, a position she has held since 2015. With a strong background in finance and accounting, Jennifer has played an important role in guiding the growth of the business which is privately owned by her family. Steritech utilizes world-leading sterilization technologies including gamma irradiation, E-beam, and X-Ray to cater to diverse industries, including healthcare, agriculture, quarantine, and fresh produce. Having personally experienced the gift of organ transplantation, Jennifer is a grateful recipient and proudly served as a Fit-for-Life Ambassador with the World Transplant Games Organization, inspiring fellow transplant recipients to embrace active and healthy lives while championing the importance of organ donation.

John Bryson is publicly named by the Bionics Institute as board director. No additional background or appointment date is inferred.

Sandra Kentish is publicly named by the Bionics Institute as board director. Professor Sandra Kentish is a Redmond Barry Distinguished Professor at The University of Melbourne. She is currently a Project Leader within the ARC Hub for Digital Bioprocess Development, the Dairy Innovation Research Hub and within the Future Fuels CRC. She was Head of the School of Chemical and Biomedical Engineering 2017-2022, Head of the Department of Chemical Engineering 2012-17 and Discipline Leader in the CRC for Greenhouse Gas Technologies (CO2CRC) for Membrane Technology from 2003-2015. Professor Kentish was selected as one of Australia’s Most Innovative Engineers by Engineers Australia in 2017 and as a Woman of Influence by the Australian Financial Review in 2018. She was elected to the Australian Academy of Technology and Engineering (ATSE) in 2019.

Alan Duffy is publicly named by the Bionics Institute as board director. Pro Vice-Chancellor, Flagship Initiatives – Swinburne University of Technology As PVC Flagship Initiatives, Professor Duffy is tasked with driving large and ambitious transdisciplinary research across our flagship research areas by actively engaging with external organisations (including government, industry, NGOs) to identify large-scale opportunities that require university-wide collaboration and the formation of coalitions of universities and partners.

Charles Bagot is publicly named by the Bionics Institute as board director. Charles Bagot is a commercial lawyer. He was a partner of Piper Alderman Lawyers and served in a number of leadership roles including as the firm’s Chair and Head of its Corporate Division. He is experienced in the fields of mergers, acquisitions and privatisations as well as corporate governance. He also had interests in the mining and resources industry, the commercialisation of intellectual property and in resolving company and board disputes. He remains a consultant to Piper Alderman. Charles was a member of the Council of the University of Adelaide and Chair of its Finance Committee until 2014. He is a Director of investment company Kalymna Pty Ltd. Charles formerly served as a Director of the Australian Submarine Company, and Director of the Australian Institute of Company Directors.

Hannah Crawford is publicly named by the Bionics Institute as deputy chair and chair of finance and risk committee. Hannah commenced her executive career with global chartered accounting firms Ernst & Young and Arthur Andersen, before joining corporate advisory firm Grant Samuel. During her 14 years as a Director of Grant Samuel she provided strategic and financial advice to a range of high profile listed and unlisted companies, including advice on mergers and acquisitions, takeovers and capital raisings. Since 2007, Hannah has been an active contributor to numerous Boards. She is currently Chair of Local Guardians, a Non-Executive Director of Confoil Australia & New Zealand and a member of the Finance and Audit Committee of Melbourne Grammar School.

Karen Hapgood is publicly named by the Bionics Institute as board director. Professor Karen Hapgood is the Deputy Vice Chancellor for Research at Swinburne University of Technology, where leads Swinburne’s Research strategy and advances Swinburne’s innovative and tech-focused R&D community. Her career has combined industry experience in the USA and Australia, including 4 years of pharmaceutical R&D and manufacturing experience with Merck & Co USA,  followed by 15 years of leadership roles in the higher education sector, all based around a common thread of manufacturing and STEM and leadership. She is an experienced leader in higher education, with expertise in research, education and industry engagement.

Phil Binns is publicly named by the Bionics Institute as chair of the board. Philip has over 30 years of experience leading organisations across the scientific and life science industries. Philip was most recently President of US based Agilent Technologies, Inc.’s Life Sciences and Applied Markets Group, retiring in April 2025. In 2008, Philip was appointed by the Federal Government to chair the Future Manufacturing Innovation Council and in 2012 served on the Prime Minister’s Manufacturing Task Force. Philip is a board member of Lightcast Discovery Ltd, Chair of Epiminder Ltd,  and is a National Advisory Councillor for the Australian Industry Group (Ai Group®). Philip is also an active investor and mentor in early-stage technology-based companies. Philip holds a Post Graduate Diploma in Management Studies and a Master of Business Administration from the University of Melbourne.

Werner van der Merwe is publicly named by the Bionics Institute as board director. No additional background or appointment date is inferred. Swinburne identifies him as Vice President, Innovation and Enterprise; the Bionics Institute biography explicitly identifies him as chair of Swinburne Ventures Limited. Prior commercialisation experience includes CSIRO, UNSW and Sasol.

The Bionics Institute of Australia is an independent Australian medical research charity founded in 1986 by cochlear-implant pioneer Professor Graeme Clark, originally as the Bionic Ear Institute. The Australian Business Register identifies ABN 56 006 580 883 and legal entity type Australian Public Company; this legal designation does not establish a stock-exchange listing. It has been registered with the Australian Charities and Not-for-profits Commission since 3 December 2012. Based at St Vincent’s Hospital Melbourne in Fitzroy, it combines neuroscience, biomedical engineering, preclinical research and clinical collaboration to develop devices and therapies. Its published programs cover hearing and vision, brain disorders, movement and balance, autoimmune disease and chronic conditions. Research includes vagus nerve stimulation, optogenetic and electrical neuromodulation, personalised transcranial magnetic stimulation, implantable epilepsy monitoring, infant hearing assessment, objective tinnitus measurement, and wearable or extended-reality neurological diagnostics. These programs span research, preclinical development and clinical trials; regulatory approval of a spin-off product does not establish approval of every Institute technology. The current public directory names 60 board members, executives, researchers, capability and support leaders, and clinical collaborators. Current news additionally names XR researcher Hamish MacDougall and epilepsy ambassador Neil Balme. Phil Binns is the current board chair, supported by deputy chair Hannah Crawford; former chair John Stanhope is recorded historically. Committee memberships are qualified by their annual-report or news publication, rather than assumed continuing employment. The Institute commercialises research through spin-off equity and contracts alongside philanthropic support, competitive government grants and charitable research loans. Its 2023–24 report explicitly identifies equity in Epi-Minder, DBS Tech, Neo-Bionica, NIRGenie, Bionic Vision Technologies and PolyActiva. Neo-Bionica ownership is recorded with undisclosed stake, price and date, separate from Breakthrough Victoria’s convertible note and government grants. A specific Helmsley grant of USD 3,189,010 awarded 9 July 2024 supports adaptive vagus nerve stimulation for Crohn’s disease over 36 months; the Institute’s rounded USD 3.2 million/AUD 4.8 million announcement represents the same award. Grant awards, annual fundraising totals and its internal incubator program are not private venture fund closes or cumulative equity rounds.

Aaron Nelson is a physician-scientist and life-sciences venture investor. Novartis Venture Fund’s own biography identifies his earlier investing role at dRx Capital, the Novartis–Qualcomm joint investment company focused on digital medicine. His prior Novartis work included technology strategy, the Trials of the Future program and investigative toxicology leadership. His education includes medicine at Tufts, cell and microbiology at the University of Pennsylvania and Karolinska Institute, and an undergraduate degree at Cornell. dRx general-partner status is also published in the RESI organizer’s original2016 program; no current dRx or current NVF employment inferred from historical web pages. Aaron joined Venture Investments (US) Inc. in June, 2025. Previously, Aaron was Managing Director at the Novartis Venture Fund, leading Seed & Series A investments in therapeutic drug discovery projects.   He also helped a digital health investment program at Novartis, called dRx Capital. Before working as an investment professional, Aaron worked on across multiple Research & Development units within Novartis, including Trials of the Future and Investigative Toxicology. Aaron earned a BA at Cornell University, a PhD in Cell and Microbiology at the University of Pennsylvania and conducted post-doctoral studies at the Karolinska Institutet, and received an MD from Tufts University.

Carolyne Zimmermann is a life-sciences business-development executive and a former founding member and General Partner of dRx Capital. SonoThera’s original appointment biography credits her with leading dRx initial investments in Omada Health and Cala Health. Her published career includes senior business-development and licensing leadership at Novartis, transactions and innovation partnering at Johnson & Johnson, Chief Business Officer at 4D Molecular Therapeutics and subsequently SonoThera. She earned an engineering-sciences BS at UC San Diego and an MBA at Columbia Business School. The dRx affiliation is historical and not a current fund position.

Jack Young is a technology and digital-health venture investor and former General Partner of the original Novartis–Qualcomm dRx Capital joint venture. Deutsche Telekom Capital Partners’ own April2016 appointment release credits him with launching dRx Capital during his earlier Qualcomm Ventures North America and Qualcomm Life Fund leadership. His published investment background includes mobile health and healthcare services, with earlier leadership at ZTE, Nokia,3Com,GDC and Nortel. He earned an electrical engineering MS from the University of Calgary and an MBA from McGill. His dRx role is historical; the exact last employment day is undisclosed.

Lucian Iancovici is a physician and life-sciences investor. Issuer SEC biographies identify his General Partner service at dRx Capital from January2015 to October2017 and earlier leadership of Qualcomm Life Fund from2012 to2017. He subsequently joined TPG in2018. His background includes McKinsey healthcare consulting, internal medicine training at Columbia University Medical Center, and a BA in economics and an MD from Tufts University. His authentic portrait is published by Yembo in its named investor section. The dRx appointment is historical and has no invented full-day employment dates.

Neil Tiwari is a venture investor with biomedical engineering and healthcare technology experience. Science37’s own SEC biography identifies his dRx Capital Principal role from September2017 to April2019 and Managing Director role from April2019 to May2021; Cala Health’s2019 release calls him General Partner. He subsequently joined Magnetar, whose March2026 own release identifies him as Managing Director. His education includes BS and MS degrees in biomedical engineering from Northwestern and an MBA from UC Berkeley’s Haas School. His dRx roles are historical; no first-of-month employment dates are invented.

Thomas Kluz is a healthcare and industrial-technology venture investor, also known as Tom Kluz. His published participant biography identifies him as a former General Partner at dRx Capital and former global healthcare investment leader at Qualcomm Ventures and Qualcomm Life Fund. He subsequently became a managing investment partner at Niterra Ventures, whose own current roster supplies his original portrait. His background includes Providence Ventures and Adams Street Partners, and investments or board work involving digital-health and medical-device companies. The dRx position is explicitly historical; no board participation is treated as personal cash investment.

dRx Capital is a digital-health and life-sciences technology investment brand, originally launched in2015 through dRx Capital AG, a Swiss joint venture between Novartis and Qualcomm. It backs data and digital technologies including healthcare AI, machine learning, research tools, precision medicine, clinical-trial platforms, pharmaceutical commercialization and neurological digital therapies such as Cala Health’s wearable neuromodulation. The original AG dissolved in July2021: Science37’s SEC filing confirms its interests were distributed to its two50% owners. That legal event does not establish that the dRx brand ceased: subsequent Novartis and portfolio-company primary sources describe Novartis dRx Capital as its digital-health venture program, and the FutureHealth2026 organizer lists Rana Lonnen as its Managing Director. Earlier partners are separately qualified as historical. The initial venture program was announced with up toUSD100million in capital commitments; no undisclosed final close, current AUM or new third-party fund is inferred. Verified portfolio includes Aktana, Science37, Cala Health, Flywheel, Omada and other data-driven healthcare businesses. This profile preserves historical JV and later brand context without claiming that the dissolved AG is an active legal issuer or merging it with Novartis Venture Fund or Qualcomm Ventures.

Eric Boutin is a digital-health investor, board adviser and serial entrepreneur. Harvard Business School’s own current biography identifies him as Venture Advisor at Harvard Street Advising and explicitly describes his earlier Managing Director role at Novartis dRx Capital, leading investments in pharma technology, patient care and healthcare AI. He previously founded Evolve, an AI consumer technology business acquired by HubSpot, and Good Start Genetics, acquired by Invitae, and worked with Longwood Fund on Flex Pharma. He holds an MBA from Harvard Business School and a BA in economics from Duke University. His dRx position is historical, despite stale portfolio pages retaining it.

Rana Lonnen is a healthcare technology investor, entrepreneur and molecular biologist. Novartis identified her as leader of its dRx Capital digital-health fund in2022, and the FutureHealth2026 organizer lists her as Managing Director, Novartis dRx Capital. Her published background includes biotech investing at IP Group, preclinical development at Auspherix, founding and scientific leadership at Axendos Therapeutics, Wellcome Trust-backed translational drug discovery and earlier sales and marketing at Bristol-Myers Squibb. She holds a molecular biology PhD and an MBA from Imperial College London. Her work spans healthcare IT, AI/ML-enabled research and precision medicine.

Matt Schwab is a senior associate at Vertical Venture Partners, focusing on sourcing industry-specific AI businesses beyond the Bay Area. He worked at Acorns before joining the firm while pursuing an MBA in data analytics. He studied computer science at Chapman University.

Paul Conley leads Vertical Venture Partners’ deep-technology practice, investing at the intersection of physics, chemistry and biology. Before beginning his venture career in 2007, he modeled materials at Los Alamos and founded BrightScale and Appfluent Technology. He holds computational physics and bioengineering degrees from UC San Diego and a mechanical and aerospace engineering degree from the University of Virginia. ONI’s 2022 financing release separately names him as a private investor; his personal identity is not collapsed into VVP’s institutional participation.

Brad Corona is a managing director of Vertical Venture Partners and leads its San Diego office. He joined full-time in 2016 following a year as venture partner. Earlier, he worked in Jefferies’ financial-sponsors and healthcare groups, co-founded an ecommerce company and invested alongside family offices. He also develops the firm’s AI systems for sourcing, diligence and portfolio research. He studied business economics at Brown University.

Vertical Venture Partners (VVP) is an early-stage venture-capital firm founded by David C. Schwab in 2014, with offices in Palo Alto and the San Diego area. It backs founders solving problems within specific industries, including healthcare, financial services, education, logistics and home services. Its investment models include vertical AI software, technology-enabled services and deep technology based on physics, chemistry and biology. The firm’s published directory lists four investing professionals: David Schwab, Brad Corona, Paul Conley and Matt Schwab. Its current site says it invests from its fourth main fund; SEC adviser records also identify two distinct growth funds. It has invested in neuroscience drug developer Delix Therapeutics, microscopy developer ONI, semiconductor-switch manufacturer Menlo Micro and multiple healthcare and AI software companies. The firm is legally reported as Vertical Venture Partners LLC, CRD288845, in a March2026 SEC exempt-reporting-adviser filing. Its earliest main fund was previously called Enterprise X Ventures LP and first sold interests in December2013, before the published 2014 firm founding. Latest SEC FormD notices verify USD51.3M sold for the first main fund, USD90M for FundIII, USD59.85M for FundIV and USD42.075M for GrowthFundII. These are securities sold as of respective filings, not inferred final close dates or fund assets under management; FundIV’s USD100M and FundIII’s USD110M offering totals are targets rather than amounts raised. Actual FundII and GrowthFundI cash-close totals remain unverified. VVP is distinct from The Vertical Group healthcare venture firm, Vertical Group investment bank and the Nordic Vertical consultancy. ONI’s 2022 primary announcement names VVP as a SeriesB investor; its preserved legacy participation was corrected to this verified firm after auditing all protected references, without creating another check.

Ajay Shimoga, also listed as AJ Shimoga, is a principal at The Cigna Group Ventures. He works across sourcing, due diligence, deal execution and board participation. Previously he helped build and invest in healthcare businesses at Oxeon’s Venture Studio and advised on healthcare-services mergers and acquisitions at Goldman Sachs. He holds a UC Berkeley bachelor’s degree.

Amir Debourou is a principal at The Cigna Group Ventures, working across investment sourcing, diligence, execution and board participation. His experience includes more than ten years in healthcare investing and strategic partnerships. He holds a bachelor’s degree from the University of Poitiers and an MBA from the University of Chicago Booth School of Business. Amir Debourou is identified as a Cohere Health director in the company’s May2025 SEC Form D. This source confirms a dated corporate board affiliation, not an individual cash investment or additional operating role.

Jack McNeilly is an associate at The Cigna Group Ventures, supporting sourcing, diligence, transaction execution and portfolio monitoring. He previously served as a senior associate at Boston Millennia Partners, investing across digital health, healthcare IT and pharmaceutical services. He holds a bachelor’s degree in public policy analysis and economics from Duke University.

Kristin Stafford is the operations and administrative coordinator at The Cigna Group Ventures. She brings more than twenty years of experience in business operations, project management and client engagement, including coordinating complex projects and improving processes. She holds a bachelor’s degree in communications.

Matthew Blum is a senior principal at The Cigna Group Ventures. He works on investment sourcing, due diligence, transaction execution and board participation, with more than ten years of healthcare investment and value-based partnership experience. He holds a bachelor’s degree from Brigham Young University and an MBA from UNC Kenan-Flagler.

Nikolas Koenning is a principal at The Cigna Group Ventures. He rejoined the firm after an MBA at London Business School, following venture investing and corporate development roles at UnitedHealth Group. He works across sourcing, diligence and transaction execution and holds a finance and economics bachelor’s degree from the University of St. Thomas.

Rachel Anderson leads portfolio partnerships at The Cigna Group Ventures, including strategic alignment, partnership enablement and support for invested companies. She brings more than twelve years of experience in client management, consulting, operations and strategic partnerships, and earned a bachelor’s degree from Baylor University.

Alain Lam, alsoLamSaiWai, isXiaomi vice-president/CFO andformerZeppHealth director. He joinedtheZeppboard inSeptember2024 andresigned effectiveSeptember1,2026 tofocus onXiaomi. His earliercareer includedCreditSuisse andMorganStanley investmentbanking; heholds anengineeringmaster’s fromOxford. CurrentZeppwebdirectory isstale regardinghis boardrole.

Pengtao Yu has ledZeppHealth industrialdesign sinceOctober2014. Previously he worked onwearablefitness products atMoov andconsumerproduct designs atBouldDesign andHarman. He studiedengineering atBeijingInstituteofTechnology andproduct/industrialdesign atArtCenterCollegeofDesign, receivingIDEA,iF andRedDot designawards. His authenticIDSAportrait is a historicalpublishedphoto.

Bing Xie has been aZeppHealth independentdirector sinceNovember2020. He previously served asTexasInstruments seniorvicepresident andexecutiveofficer leadingworldwide sales/applications, andheld positions atHP,BayNetworks and3Com. He studiedelectronicengineering atXidianUniversity andbusiness atClemsonUniversity.

Hongjiang Zhang is aZeppHealth independentdirector sinceFebruary2018 andventurepartner atSourceCodeCapital. His experience includesCarlyle advisorywork,AAC andXPeng boards,leadership ofKingsoft andKingsoftCloud, andMicrosoftAsia-Pacific research/development. He holds electrical-engineering degrees fromZhengzhouUniversity andTechnicalUniversityofDenmark.

Hui Wang has ledZeppHealth corporate strategy sinceMarch2020 andNorthAmerica sinceMarch2024. His earlierZepp role coveredBeijingoperations; beforejoining he researched andledproducts atLenovo andNECLabsChina. He holds aninformationengineering degree andcommunications PhD fromUSTC. He is distinct fromZepp founderWangWayneHuang.

Jimmy Lai is a finance executive andindependentdirector ofZeppHealth sinceFebruary2018, also serving oneducation andconsumerfinance boards. He formerly held CFO roles atChinaOnlineEducation,Chukong,Gamewave,DaqoNewEnergy andLinktone. He studiedstatistics atNationalChengKungUniversity andholds anMBA fromUTDallas andTexas CPA qualification. This is the corporatefinance executive, distinct from theHongKong mediaentrepreneur namesake.

Leon Cheng Deng has been ZeppHealth CFO since October2020. He previously held finance leadership roles acrossPhilips treasury,personalcare anddomesticappliances, with experience in divestitures,acquisitions andcapital markets. He holds finance degrees fromShanghaiInternationalStudiesUniversity andUniversityofAmsterdam, plus accounting certifications.

Meihui Fan has served asZeppHealth CTO sinceJuly2021 anddirector sinceSeptember2024. A founding-team member, he previously led softwarearchitecture,R&D andtheGlobalInnovationCenter afterjoining in2014. His earlier work included embedded-system engineering andtechnical leadership inHefei. He studied molecular/cellbiology andsignal/information systems atUSTC.

Mike Yan Yeung has served asZeppHealth COO sinceJanuary2015 anddirector sinceSeptember2024. He previously invested in mobileinternet,IoT andhealthcare atShunweiCapital andmanaged digitaladvertising software atMicrosoft. Earlier positions includedOracle,Netscape andMonster. He holds computer-science degrees fromBerkeley andStanford.

Wang Wayne Huang, also called Wayne Wang Huang, founded the Huami operating business in2013 and leads ZeppHealth as chairman andCEO. He previously founded embeddedLinux and tablet technology businesses and worked on switching/routing systems atHuawei. He holds an appliedphysics degree fromUSTC.

Zepp Health Corporation is a publicly listed wearable and health-technology company, founded as Huami in2013 and renamed internationally on February25,2021. The Cayman-incorporated group trades on the NewYork StockExchange as ZEPP; its principal executive offices moved to Gorinchem,Netherlands in2025. Its brands include Amazfit,Zepp Clarity andZepp Aura. Its digital health platform combines ZeppOS,AI chips,biometric sensors and algorithms; products include smartwatches,AI fitness coaching,health analytics and hearing technologies. It also invests in medical imaging and semiconductor businesses, including the confirmed neuro42 MRI/AI/robotics investment, and applies AI expertise to industrial medical imaging. Consumer wellness features are distinct from clinical devices. Current leadership includes six executives and six directors with overlapping executive/director roles; Alain Lam resigned from the board effective September1,2026, superseding the still-listed website entry. IPO and follow-on issuer proceeds are distinguished from selling-shareholder secondary proceeds, cash balances and unused credit capacity.

Executive advisor of LRVHealth with healthcare digital strategy, technology and analytics expertise. The firm describes chief digital officer responsibilities at Sutter Health and prior chief information officer work at Ochsner, following healthcare IT consulting and Epic implementation experience.

Executive advisor of LRVHealth with physician, hospital and health-system leadership experience. The firm describes GSteele Health Solutions work, former Geisinger and xG Health Solutions leadership, and previous academic medicine roles at Chicago and Harvard.

Executive advisor of LRVHealth with healthcare-system strategy and governance experience. His biography describes retirement following the Bon Secours and Mercy Health combination and prior leadership at Bon Secours and St. Joseph Health, plus corporate and nonprofit board service.

Executive advisor of LRVHealth and former Cedars-Sinai healthcare executive. The firm describes his president and CEO emeritus status, academic health-system development and healthcare policy and governance experience.

Executive advisor of LRVHealth with integrated health-system operations and consumer-experience expertise. The firm biography describes her Texas Health Resources leadership and a planned September 2026 CEO transition; the old page’s future-tense wording is not independently treated as proof the transition completed.

Executive advisor of LRVHealth with healthcare finance and governance experience. The firm describes chief financial officer responsibilities at McLaren Health Care and earlier Henry Ford Health System work.

Physician and healthcare executive published as Sachin H. Jain in LRVHealth’s biography, serving as an executive advisor to the firm. His background includes leadership of SCAN Group and SCAN Health Plan, previous CareMore and Aspire Health leadership, Merck medical information and innovation, and federal healthcare policy. This person is distinct from the existing Bessemer venture investor named Sachin Jain.

Liz Fowler is an executive advisor to Valtruis and a federal health policy expert. She previously directed the CMS Innovation Center as deputy administrator and held leadership roles at the Commonwealth Fund and Johnson & Johnson. She worked on the Affordable Care Act and Medicare legislation. Her degrees are from the University of Pennsylvania, Johns Hopkins and the University of Minnesota. Her published biography also identifies a Johns Hopkins faculty affiliation. Existing separately sourced biography: Executive advisor of LRVHealth with federal health-policy, payment reform and care-model experience. Previously led the CMS Innovation Center and held policy roles at the Commonwealth Fund, Johnson & Johnson, the National Economic Council and Senate Finance Committee.

Executive advisor of LRVHealth with health-system strategy, innovation, population health and payer-provider partnership experience. The firm describes his strategy leadership at Allina and earlier executive work at Mayo Clinic.

Executive advisor of LRVHealth and healthcare economist, focused on payment systems, insurance benefit design and healthcare-market regulation. The firm biography describes Harvard health-policy research and advisory work on Medicare policy.

Executive advisor of LRVHealth with pharmaceutical services and healthcare operations experience. The firm describes leadership at CareTria, prior executive-in-residence work at Frazier, senior Cencora roles and co-founding Shields Health Solutions.

Executive advisor of LRVHealth with computational epidemiology and healthcare innovation expertise. The firm biography describes his innovation leadership at Boston Children’s Hospital and research on AI, data mining and public-health surveillance. Outside academic and hospital titles are separate from the venture advisory role.

Executive advisor of LRVHealth. The firm describes her healthcare software, federal policy and technology background, including senior leadership at Booz Allen Hamilton and operations and strategy at CareScience. Her LRV affiliation is advisory, distinct from outside executive positions.

Executive advisor of LRVHealth with physician leadership and health-policy experience. Previously chief medical officer at CVS Health and Aetna and president of the Brigham and Women’s Physician Organization; the firm biography also describes academic work at Harvard.

Chief financial officer of LRVHealth with venture and private-equity fund operations experience. Previously worked on finance, valuation, capital planning and investor communications for Fidelity’s Devonshire Investors and supported Bain Capital’s credit business.

Director of operations at LRVHealth with healthcare, academic and nonprofit administrative experience. Previously managed financial and administrative functions at Tufts’ Cummings School of Veterinary Medicine and led Community Harvest Project.

Partner of LRVHealth, focused on care delivery, behavioral health, workforce transformation and government-sponsored payers. Previously led Tufts Health Ventures and held operations and strategy roles at athenahealth, following investment and consulting work at Goldman Sachs and Bain.

Director of value creation at LRVHealth with healthcare strategy and operational transformation experience. Previously led analytics and strategic initiatives at Access TeleCare and worked with health systems as an engagement manager at McKinsey.

Managing partner of LRVHealth since joining in 2022, focused on connecting entrepreneurs with healthcare incumbents and pharmacy innovation. Previously spent nearly two decades at CVS Health, culminating in chief strategy and business development leadership and establishing CVS Health Ventures. Earlier experience includes management consulting and law.

Managing partner of LRVHealth with healthcare information-technology operating experience. Previously led healthcare informatics at Premier and enterprise solutions at Eclipsys. His current work includes advising healthcare strategic limited partners and building technology and innovation relationships across the network.

Principal of LRVHealth, working on healthcare investment sourcing, diligence, underwriting and portfolio value creation. Previously held strategy and payer-partnership roles at ChenMed and consulting positions at Charles River Associates and FTI Consulting.

Executive assistant and marketing associate at LRVHealth, supporting partners and coordinating firm events. Previously taught biology, anatomy and environmental science in Grafton public schools and organized community events.

Co-founder and general partner of LRVHealth, whose biography describes joining as co-founder in 2001. Previously an investor at Firepond Partners and co-founder and chief executive of healthcare transactions company NaviNet, following leadership at Pegasus Medical Technologies. He developed healthcare investing across the firm’s early funds and strategic health-system partnerships.

Director of marketing at LRVHealth, responsible for brand, communications, events and community initiatives. Previously an early marketing employee at medical-training software company Level Ex and worked in healthcare marketing and communications agencies.

Vice president of strategic engagement at LRVHealth, leading strategic limited-partner engagement, market intelligence and portfolio value creation. Previously advised healthcare organizations at Oliver Wyman and led corporate strategy work at Optum and UnitedHealth Group.

Senior associate of LRVHealth, supporting sourcing, diligence, execution and portfolio operations. Previously worked on onboarding and strategic projects at Cohere Health and electronic health-record workflows at Mass General Brigham, including behavioral health programs.

415 Capital Management GmbH is a Munich medical-technology venture capital manager investing in clinical through commercial businesses in Europe, Israel and North America. Its focus includes cardiovascular and neurovascular disease, neuromodulation, medical robotics and imaging, and patient monitoring. Portfolio exposure includes ReEmerge’s brain-stimulation therapy and Laza Medical’s AI-assisted cardiovascular imaging and robotics. Its current public directories list ten investment-team staff, three senior advisers and thirteen external clinical advisers. The founders’ earlier CardioVentures investments and commercialized technologies form a predecessor track record. Fund I’s first close was announced in January 2020 with its amount undisclosed; Fund II’s October 2024 announcement describes a EUR150 million target, with no verified final-close amount.

Executive Assistant at 415 Capital since 2025. Has a background in humanities, languages, teaching and research, and previous experience supporting a Swedish private-equity firm. The current directory uses Habich; the individual biography URL retains Hadziabdic.

Investment Intern at 415 Capital since July 2026. Pursues life-sciences engineering at EPFL and completed master’s thesis research at Dana-Farber and Harvard. Supports the firm’s medical-technology investment work.

Managing Director for the US and Investment Committee member at 415 Capital. Previously led cerebral embolic-protection developer Claret Medical and served as Conor Medsystems’ COO. Holds a doctorate from Brown University and chairs CVPath Institute.

Co-founder, General Partner and Chief Financial Officer of 415 Capital. Previously worked in finance leadership at Boston Scientific and Chiron Adatomed, following EY. Also co-founded medical-device distribution businesses including CoRRect and Regis Medical.

Associate at 415 Capital since 2021. Studied engineering and industrial biotechnology at the Technical University of Munich. Works on medical-technology investment diligence and financing.

Cardiac electrophysiologist at Beth Israel Deaconess Medical Center and faculty physician-investigator at its Smith Center. Listed by 415 Capital as an external Senior Clinical Advisor. His institutional research profile publishes his named biography and portrait.

Interventional cardiologist and vascular-intervention researcher at Beth Israel Deaconess Medical Center. Listed by 415 Capital as an external Senior Clinical Advisor; this advisory affiliation does not imply employment at the investment firm.

Co-founder and Chairman Emeritus of 415 Capital. Has decades of medical-device commercialization and entrepreneurship experience, including leadership in Germany for Boston Scientific and earlier work at St. Jude Medical, Gore and American Hospital Supply.

Co-founder and General Partner of 415 Capital. Previously worked in medical-device business development at Regis Medical and leveraged finance at HSBC. His investment work includes R3 Vascular and TRiCares; studied economics at the University of Toronto.

Senior Investment Analyst at 415 Capital since 2024. Holds mechanical-engineering and medical-engineering degrees from the Technical University of Munich and supports medical-technology investment evaluation.

Principal at 415 Capital, joining in 2019. Previously worked at 4K Invest and in healthcare investment banking at RBC. Holds degrees from King’s College London and Cambridge and supports portfolio-company investment and board work.

Associate Professor of Medicine at Duke University with clinical and research work in advanced heart failure. Listed by 415 Capital as an external Senior Clinical Advisor. Duke’s current appointment supersedes the investment firm’s older assistant-professor wording.

Angiology specialist and clinical researcher at the Medical University of Graz, where she heads the angiology division. Listed by 415 Capital as an external Senior Clinical Advisor. The university publishes her professional directory entry and portrait.

Investment Analyst at 415 Capital since 2025. Previously worked in investment banking at BTG Pactual and healthcare consulting at ZS. Studied economics at Insper and finance at Columbia University.

Senior Venture Partner at 415 Capital and medical-technology entrepreneur. Co-founded CoRRect Medical and Reverse Medical and has experience in neurovascular product development, endovascular clinical work and biomedical engineering.

Cardiologist and vascular-biology researcher, formerly Director of Cardiology at Carmel Medical Center in Haifa. His research includes gene and cell therapy. Listed by 415 Capital as an external Senior Clinical Advisor; his author profile publishes a default avatar.

Professor and interventional-cardiology specialist at Erasmus Medical Center in Rotterdam. Listed by 415 Capital as an external Senior Clinical Advisor. His authenticated European Society of Cardiology profile publishes a named portrait.

Cardiologist affiliated with McGill University and the McGill University Health Centre, with expertise in structural-heart interventions. Listed by 415 Capital as an external Senior Clinical Advisor; McGill publishes his named professional profile and portrait.

Clinical Professor of Surgery at the University of California, San Francisco, specializing in vascular and endovascular surgery. Listed by 415 Capital as an external Senior Clinical Advisor. UCSF publishes his authenticated faculty profile and portrait.

Cardiologist and Technion Professor Emeritus; formerly Director of Rambam Health Care Campus from 2006 to 2019. Listed by 415 Capital as an external Senior Clinical Advisor. Rambam’s biography distinguishes his former hospital-director appointment.

Partner and Chief Medical Officer at 415 Capital. Trained in cardiothoracic surgery and holds a doctorate in cardiovascular medicine. Combines clinical and research experience with diligence and investment work in medical technology.

Interventional cardiologist affiliated with Oxford University Hospitals and Cleveland Clinic London. Listed by 415 Capital as an external Senior Clinical Advisor. His own physician website publishes his professional biography and original portrait.

Senior Advisor to 415 Capital and cardiac surgeon associated with the University of Michigan. Specializes in mitral-valve repair and has co-founded medical-device businesses including Pipeline, Millipede and Laminar. His firm affiliation is advisory.

Interventional cardiologist specializing in structural-heart procedures. Joined NYU Langone in 2026 to lead interventional cardiology after his Columbia appointment. Listed by 415 Capital as an external Senior Clinical Advisor; the firm’s older institutional wording is historical.

Cardiologist leading innovative interventional heart medicine at Herz- und Gefäßzentrum Bad Bevensen. Listed by 415 Capital as an external Senior Clinical Advisor. His hospital publishes a named appointment announcement and original portrait.

Biora Energy builds a distributed biomass pellet supply platform in India. It converts underused agricultural and industrial residues into solid biofuels for industrial boilers and power plants, using reliable feedstock sourcing and traceable supply chains. Its products include wood-waste pellets, pellets made from mustard husk, rice husk, paddy straw and sugarcane bagasse, and customised blends matched to customer requirements for heating value, moisture and ash. The company aims to connect rural waste suppliers with industrial users seeking alternatives to coal.

Helios provides residential rooftop solar systems in the Philippines, combining system design, installation, permits, financing assistance and after-sales support. Its solar mortgage model lets homeowners spread installation costs through monthly payments using partner banks and lenders, helping households adopt solar without paying the full system cost upfront. Helios coordinates the process from a home assessment and solar proposal through loan applications and installation, then provides remote performance monitoring and customer support. The company operates as Helios (PH) Sustainable Energy Corp. and was established in 2023.

Lumio Solar distributes solar-powered appliances and equipment for households, small businesses, farms and communities in the Philippines. Its range includes fans, refrigeration, lighting, water pumps and portable power stations that require little or no installation. It combines product distribution with inventory fulfilment, nationwide delivery, local hubs, warranties and after-sales service. Based in San Fernando, Pampanga, Lumio is expanding access to practical solar products through retail partnerships and community demonstrations, starting in Central Luzon and Metro Manila.

Neoterra India develops solar-compatible air-conditioning systems for homes and businesses. Its Smart Solar AC can use compatible solar power directly, switch to grid electricity when needed and integrate with configured solar and battery systems. The product offers adjustable cooling capacity, Wi-Fi control and air filtration. Neoterra combines equipment with site assessment, installation and after-sales support, aiming to make cooling more affordable and reduce the grid electricity needed by Indian households and commercial customers.

NuMat Bamboo develops and manufactures engineered bamboo materials for construction, interiors and furniture. Founded in Singapore with manufacturing in Manolo Fortich, Bukidnon, Philippines, it integrates local bamboo sourcing, harvesting, primary processing and board production to offer alternatives to conventional plywood and timber. Its products include NuForm concrete formwork panels, NuWeave woven decorative wall boards and NuBrid boards for furniture and cabinetry. The business originally launched mobile bamboo processing units and a BambooPreneur partnership programme that lets rural landowners participate in its supply chain; its current offering extends into engineered finished panels and materials.

Sales and distribution leader with previous experience at Zee Entertainment Enterprises.

Entrepreneur building solar-compatible cooling products for India.

Helios publishes him as Edmund Martinez; its investor 100×100 uses Edmund Daniel Martinez and identifies him as co-founder and CEO.

Publicly lists Numat PH as her current affiliation. Her exact job title is not disclosed in the public profile.

Founder and CEO named in the investor’s November 2024 launch announcement; his current company hiring profile identifies him as CEO of NuMat Bamboo.

Leads global market development and revenue strategy for NUMAT Sustainable Manufacturing, focusing on commercial adoption of engineered bamboo materials.

Named Nicholas Toh by the CEO; the company’s current HR Manager hiring post uses Nick Toh for the same Chief of Staff role.

Retail and commercial operator with more than two decades of experience, including senior leadership at SM Malls Online. Also publicly uses Rey Angelo S.

Felicia Hosey, RAC, is identified as Cleerly’s Senior Director of Regulatory Affairs in its July 2026 FDA submission. She is a regulatory consultant and Managing Director of MDDX Solutions, with experience in medical devices and diagnostics, and serves on indieMedTech’s board. Her Cleerly appointment may be a consulting engagement; a full-time employment contract is not inferred.

Quinn Cornelius is a publicly identified Gates Ventures professional. His public professional profile identifies Gates Ventures affiliation, CFA certification and an MBA from Duke University’s Fuqua School of Business. The reviewed primary source does not disclose his exact office title or any personal cash investment.

Managing partner of Breakthrough Energy Ventures and executive director of the broader Breakthrough Energy organization; formerly worked at the Bill Gates investment office. Legal SEC name Rodrigo Guidero.

Eric Heinz serves Madison Scientific as Advisor. The company describes him as founder and managing partner of Heinz Ventures. The September2025 issuer announcement also identifies Eric S. Heinz as its founder and CEO/managing partner. Eric S. Heinz is founder and managing partner of Heinz Ventures. His own biography describes medical-device engineering, commercialization, corporate development and governance roles at Medtronic, Intuitive Surgical, Smith+Nephew and Titan Medical. He holds a bioengineering degree from Illinois, engineering-management degree from Christian Brothers and MBA from Northwestern; he is a registered patent agent. Current manager biography identifies his Madison Scientific advisory role.

Alexei Mlodinow serves Madison Scientific as Advisor. The company describes him as a surgeon and serial entrepreneur.

Joseph Batterman is named by Madison Scientific as a Batterman-family hydrocephalus advocate in its advisory directory. The authentic company photograph shows the family together; it is a shared family image rather than an individually identified headshot. No individual face position, medical history or professional credential is inferred.

Angela Batterman is named by Madison Scientific as a Batterman-family hydrocephalus advocate in its advisory directory. The authentic company photograph shows the family together; it is a shared family image rather than an individually identified headshot. No individual face position, medical history or professional credential is inferred.

Christopher Batterman is named by Madison Scientific as a Batterman-family hydrocephalus advocate in its advisory directory. The authentic company photograph shows the family together; it is a shared family image rather than an individually identified headshot. No individual face position, medical history or professional credential is inferred.

Haven Allen serves Madison Scientific as Board Member. The September2025 issuer financing release identifies him as chief executive of mHUB Ventures. Board membership alone is not evidence of a personal investment.

Elizabeth Hagerman serves Madison Scientific as Board Member. The current issuer directory confirms this role; an expanded professional biography is not published there.

John Slump serves Madison Scientific as Board Member. The current issuer directory confirms this role; an expanded professional biography is not published there.

Joshua Carson serves Madison Scientific as Board Member. The March2025 financing release identifies him as a venture manager at WARF Ventures. This company board appointment does not establish a personal cash investment.

David Wesner serves Madison Scientific as Chief People Officer & VP, Operations. The current issuer directory confirms this role; an expanded professional biography is not published there.

Bermans Iskandar serves Madison Scientific as Chief Medical Officer and Board Member. The current issuer directory confirms this role; an expanded professional biography is not published there.

Alexander van Rosendael serves on Cleerly’s Scientific Advisory Board. ESC’s 2025 contributor profile identifies his Leiden University Medical Center affiliation.

Koen Nieman serves on Cleerly’s Scientific Advisory Board and works in cardiovascular medicine and radiology at Stanford.

Maros Ferencik serves on Cleerly’s Scientific Advisory Board and researches coronary CT imaging at Oregon Health & Science University.

Ibrahim Danad serves on Cleerly’s Scientific Advisory Board. The current ESC profile identifies his Radboud University Medical Center affiliation; recent primary research identifies cardiology. The Cleerly directory’s radiology title is not adopted as a separate current appointment.

Ricardo Cury serves on Cleerly’s Scientific Advisory Board. Its directory identifies his diagnostic radiology leadership at Florida International University.

Andrew Choi serves on Cleerly’s Scientific Advisory Board and researches cardiovascular imaging at George Washington University.

Victor Y. Cheng serves on Cleerly’s Scientific Advisory Board. His institutional biography identifies cardiovascular CT leadership at Allina’s Minneapolis Heart Institute.

Ecomet Logistics is an Indian multimodal logistics company that combines rail with road freight to make long-haul shipping more efficient and less carbon intensive. It is building a discoverable, standardized operating network for rail-based freight with end-to-end shipment visibility. Its services include door-to-door full-truckload and less-than-truckload transport, station-to-station container rail freight, warehousing and supply-chain consulting. It serves industries including retail, manufacturing, agriculture, pharmaceuticals, energy and construction.

Muun AI is a Singapore industrial software company that converts existing machine and process telemetry into explainable operational intelligence. Its platform labels sensor signals and production cycles, establishes asset-specific performance baselines, detects drift and anomalies, and produces ranked recommendations with traceable evidence. It works with data exports, historians, databases and live feeds, helping operators reduce excess processing, energy consumption and waste while improving throughput and equipment reliability. Its approach supports human review and introduces prediction or automation only after operational value is demonstrated.

Founder and CEO of Muun AI, with experience building applied AI systems. The company’s financing announcement identifies her as an AI veteran holding three machine-learning patents.

Nadim Yared is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes CVRx, Medtronic Navigation. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Tom Wilder is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes VS3 Medical, Neuros Medical, Sequent Medical. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Dennis Wahr is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes Nuvaira, Lutonix, Velocimed. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Leslie Trigg is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes Outset Medical, Lutonix. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Art Taylor is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes Topera, & CFO, Kyphon. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Roy Tanaka is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes J&J Biosense Webster. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Aaron Smith is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes Artelon, Amniox Medical. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Jeroen Bax serves on Cleerly’s Scientific Advisory Board and is a cardiologist at Leiden University Medical Center specializing in cardiac imaging.

Pete Sommerness is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes Enterra Medical, Respicardia, Boston Sci EP. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.